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ABSTRACT
Platelet adhesion is regulated by both activators, such as adenosine diphosphate,
and inhibitors, such as nitric oxide (NO). Both agents are released on platelet activation,
so that platelets initiate both positive and negative feedback systems. In vivo platelet
adhesion models generally consider the effects of platelet activators and inhibitors
separately. The goal of this study was to create an environment in which interplay
between positive and negative feedback can be observed together and in which the roles
of endogenous and exogenous platelet activators are distinguishable. The results are
expected to be applicable to the design of stents, which are susceptible to thrombus
formation, and which provide multiple adjacent regions where platelet-released agents
can interact with one another.
To distinguish between the role of exogenous and endogenous agents,
microchannels were produced that had multiple thrombogenic (fibrinogen) regions
separated by non-thrombogenic (BSA-coated) regions. This geometry reveals the effect
of agents released from different thrombogenic regions on one another. Adhesion was
quantified by percent platelet surface area coverage.
Surface area coverage differed between the upstream and downstream sides of the
thrombogenic regions. Positive and negative feedback effects were enhanced by
increased platelet production of activator and inhibitor. In contrast, when the NO donor
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DPTA NONOate was added, with the intent to overwhelm the endogenous feedback, a
more uniform spatial distribution of adhesion was obtained.
Though these agonists, activator (ADP) and inhibitor (NO), act on different
receptors through different signaling pathways, they all lead to increase or decrease in the
intracellular Ca2+ concentration ([Ca2+]) depending on the agonist produced. Ca2+ is a key
component and serves as second messenger in all cells regulatory processes. The increase
in [Ca2+] leads to several steps of activation. The process leading Ca2+ to increase and
decrease and its underlying mechanisms remained largely unknown.
To examine Ca2+ response, platelets were loaded with the Fluo-4 Ca2+ ion
indicators and fluorescence waveform was monitored. We found that Ca2+ response
increased dose dependently with addition of an activator (ADP) and addition of
endogenous (L-Arginine) and exogenous (DPTA NONOate) NO donor showed decrease
in Ca2+ response in ADP stimulated platelets.
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CHAPTER 1
INTRODUCTION

1.1

Cardiovascular Diseases and Atherosclerosis

The main cause of cardiovascular disease (CVD), including myocardial infraction
(MI), heart failure, stroke, and claudication, is atherosclerosis [1]. This condition affects
about one-third of all deaths in people older than 35 years every year, and the percentage
is expected to continue increasing in developing countries in coming years [2].
Atherosclerosis involves lipid and macrophage accumulation inside the lumen of large
arteries. Atherosclerotic plaque disruption leads to platelet activation, platelet
aggregation, and consequent atherothrombotic episodes [3]. Figure 1-1 illustrates the
development and progression of atherosclerosis and thrombosis through platelet
activation and aggregation [4].
Atherosclerosis plaque ruptures cause thrombus formation, which triggers
cardiovascular diseases [5][6]. It is generally not localized to one region or one lesion,
but is more irregular and frequently diffuse, forming multiple thrombi that alter
hemodynamics of the system. Platelet physiology and its functions play a key role in
initiation and progression of atherosclerotic lesions through release of chemical agents,
granule proteins, and micro particles by interacting with low density lipid proteins,
immune cells, and endothelial cells [7]. Thus, effective primary prevention strategies and
tools that can identify risk groups are needed worldwide. Models that elucidate dynamic
1
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changes and early prediction of blockages in blood vessels can assist in the development
of these needs.
1.2

Positive and Negative Feedback Effects on Thrombus Formation

The atherosclerotic plaque rupture by platelets is a pathological stimulus for
thrombus formation. Thrombus formation alone has both spatial and temporal features
embraced with diverse biochemical, biomechanical, and biophysical interactions. Figure
1-1 summarizes the events leading to the formation of a thrombus [8].

Figure 1-1: The mechanism leading to thrombus formation [8].

The complexity of the process increases when multiple thrombi interact spatially
and temporally. Platelet-to-platelet signaling is expected to have both positive and
negative feedback effects on thrombus formation [9]. Generally positive feedback leads
to rapid responses and must be regulated by negative feedback to stop unbounded growth
and oscillatory behavior.
Platelets generally experience numerous extracellular signals at same time and
respond to a complex combination of primary and secondary activator signals in addition
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to opposing inhibitory signals. The interaction is regulated such that each response
triggered by a single agonist. But a more sophisticated approach is needed to incorporate
multiple agonists and pathways, which themselves interact into a signaling network.
When blood interacts with a series of activators from the vessel wall (positive feedback)
and inhibitors (negative feedback), the combined effect of activating and inhibiting
network led to many complications related to platelets [10][11].
1.3

Endogenous Platelet Activators and Inhibitors

Platelet activation, aggregation, and adhesion depend on exogenous and
endogenous activators and inhibitors [12]. The interaction between inhibitors such as
nitric oxide (NO) and activators such as adenosine diphosphate (ADP) depends on the
temporal sequence of release of these agents [13][14]. The positive feedback, originating
in endogenous agents that recruit and activate additional platelets, leads to regions of
rapid thrombus growth, but endogenous negative feedback compounds can inhibit this
growth. Consequently, the overall growth of a downstream thrombus will be changed by
an upstream thrombus in a manner that depends on whether the activators or the
inhibitors from the upstream thrombus are more dominant and cannot be predicted.
A method to study the effects of spatial relationships on platelet adhesion is to
develop a model that includes platelet adhesion at the site of interfaces between
activating region and non-activating regions on the flow surface, such a model can
elucidate the relative effects of positive and negative feedback at different regions in the
flow. The focus of this dissertation is the activator ADP and inhibitor NO when supplied
exogenously in various ratios or triggered endogenously.
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1.4

NO and NO Donors

The most important known endogenous vasodilator secreted by vascular
endothelium is NO [15]. NO is produced within platelets by enzyme NO synthase
(eNOS) and effectively inhibits platelet adhesion and aggregation [16]–[18]. It is formed
by a twostep oxidation process of L-Arginine (a semi essential amino acid) to Lcitrulline, as shown in Figure 1-2. It is a byproduct of this conversion, which involves
Nicotinamide Adenine Dinucleotide Phosphate (NAPDH) and oxygen, with the
intermediate NG-hydroxy-L-Arginine [19].

Figure 1-2: Pathway leading to NO from L-Arginine to L-citrulline through the reaction
catalyzed by NOS enzyme [20].

It inhibits platelet activation by increasing cyclic-3’5’-guanosine monophosphate
(CGMP) with direct stimulus of the enzyme soluble guanylate cyclase (sGC) [18][21].
sGC stimulates the formation of cyclic GMP from GTP. CGMP activates protein kinase
GMP (PKG) which blocks Phospholipase C which in turn blocks inositol triphosphate
(IP3) receptors. Figure 1-3 diagrams the mechanism of NO and platelet inhibition.

5
NO + Guanylate
Cyclase

↑cGMP

cGMP + PDE III

↑cAMP

↑cAMP, ↑cAMP

↑PKG, ↑PKA

↓PKC Activation,
↓Ca++ Mobilization

Platelet Inhibition,
Vasodilation

Figure 1-3: Mechanism of NO Inhibition [8].

NO production by platelets is low in patients with cardiovascular risk factors,
heart disorders, and coronary heart disease, and in some situations, it also leads to arterial
thrombotic disease [22][23]. Excessive production of NO by iNOS also leads to many
harmful effects such as inflammation and initiation of apoptosis [24]. Thus, exogenous
NO donors, which are pharmacological compounds that release NO instantly, are used
widely in cardiovascular physiology and therapeutics to evaluate the role of NO in
platelet Ca2+ signaling and its functions [25][26].
The replacement of endogenous NO by exogenous NO donors like
Dipropylenetriamine NONOate (DPTA NONOate) in platelet pathobiology has become
great foundation in the field of cardiovascular medicine [27]. Our aim is to study how
exogenous NO donors modulate the bioactivity of endogenously produced NO on ADP
stimulated platelets.
1.5

Calcium Signaling in Platelets

Platelets are activated through many signaling pathways. Various agonists bind to
specific receptors to trigger platelet function in a dose-dependent manner. Platelets
respond to collagen, ADP released from activated platelets, thromboxane, and thrombin
while simultaneously being modulated by NO and prostacyclin [28]. These chemical
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agents either increase or decrease intracellular Ca2+ concentration ([Ca2+]) depending on
the agonist produced, though they act on different receptors through different signaling
pathways. Ca2+ is a key component that serves as second messenger in all cells
regulatory processes. The increase in [Ca2+] leads to several steps of activation [29][30].
The process leads Ca2+ to increase and decrease, and its underlying mechanisms remain
largely unknown. The major Ca2+ sources for platelet activation and inhibition are not
fully identified. Platelet activation models generally consider the effects of platelet
activators and inhibitors separately. This study was undertaken to determine the
interaction between positive and negative feedback effects produced by an activator
(ADP) and an inhibitor (NO), as measured by the effect on [Ca2+].

1.6

Role of Calcium in Platelet Activating and Inhibiting Pathways

Ca2+ is an essential second messenger and a highly versatile intracellular signal
that process over a wide range of platelet functions. Ca2+ signaling uses an ‘ON’ reaction
that introduces Ca2+ into the cell and an ‘OFF’ reaction that removes it from the
cytoplasm. Channels in plasma membrane and endoplasmic/sarcoplasmic reticulum are
responsible for ON reactions whereas pumps and exchangers carry out OFF reactions.
The agonists act through two classes of signaling receptors, which are immuno receptor
tyrosine-based activation motif (ITAM-Coupled) receptors and G protein-coupled
receptors (GPCR). These receptors trigger different signaling pathways and activate
phospholipase (PLC) isoforms. PLC isoforms produce diacylglycerol (DAG) and IP3
(Inositol triphosphate receptors) thereby inducing the release of Ca2+ from dense tubular
systems in endoplasmic reticulum. This store depletion triggers a large Ca2+ influx across
the cytosol called store operated Ca2+ entry (SOCE), which is major route of Ca2+ influx
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in platelets. Figure 1-4 illustrates the Ca2+signaling in ADP-induced platelet activation
[31].

Figure 1-4: Ca2+ signaling in ADP-induced platelet activation and aggregation [31].

Endothelial cells inhibit platelet inhibition through production of NO by the
enzyme endothelial NOS (eNOS). NOS is strictly a Ca2+/CaM dependent enzyme which
enters platelets and activate enzyme sGC, which then stimulates the formation of cyclic
GMP from GTP. CGMP activates PKG, which blocks phospholipase C, which in turn
blocks IP3 and decreases the intracellular calcium concentrations. Exogenous donors
such as DPTA NONOate are converted to NO and could replace deficient levels of NO in
patients with coronary artery disease (CAD).

8

Figure 1-5: Endogenous and Exogenous NO signaling in Platelets [32].

Figure 1-5 illustrates the process; NO release from endothelial cells activates
soluble guanylate cyclase with increases the level of intracellular cyclic guanosine
monophosphate (cGMP) and thus causing vasorelaxation, platelet disaggregation, and
prevention of platelet adhesion by inhibiting the [Ca2+] levels in platelets [32].
Replacement with exogenous NO donors is helpful in patients with the impaired activity
of the endothelial L-Arginine/NO pathway.
1.7

Analysis of Need

Many models are being developed for platelet-mediated thrombo-genesis, but
these models separately consider the effects of platelet activators and inhibitors.
Combined effects of positive and negative feedback signals acting at various locations are
the main controlling factors of the final thrombus size. To explain these effects, positive
and negative feedback effects need to be studied simultaneously on regions in which
thrombus formation is active next to regions in which thrombus is prevented. This
configuration allows examining the effects of platelet derived activators and inhibitors in
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one region influences platelets in a different region under varying shear conditions. This
type of study requires spatially varying proteins surfaces coated with proteins. The
limited knowledge about the relation between platelet function and the adhesion patterns
that would occur made us to propose a model which examines and compare platelet
adhesion and its combined effects on positive and negative feedback interactions on an
improved micro channel patterned with fibrinogen using Xurography. The experiments
done are an extension of the work done by Sanakam, and Adams. Sanakam and Adams
built a micro channel patterned with thrombogenic regions and non-thrombogenic region
(one that has thrombogenic and non-thrombogenic surfaces side-by-side) to study
simultaneous positive and negative feedback effects on regions in which thrombus
formation is active next to regions in which thrombus is prevented. Their results suggest
an influence of agents secreted by upstream platelets on downstream adhesion, but some
of the results were not statistically significant, and there is need to collect enough data to
be able to quantitatively model the effects [33][34]. Combined positive and negative
feedback signals acting at various locations are the main controlling factors of the final
thrombus size.
Sanakam and Adams did not concentrate on the combined effects of chemical
agents and did not study the percent surface area coverage and its effects when
production of NO is prevented with the addition of L-NMMA or ADP to the plasma
along a thrombogenic surfaces. These endogenous agents will be used to test various
strategies to inhibit thrombus formation under flow conditions and to minimize the
impact on hemostasis.
Sanakam and Adams also did not study exogenous NO donors. A Xurography
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technique was used to layer each micro channel with collagen or fibrinogen or albumin
and compared the percentage of platelets covered on the surface area. Platelets were
extracted from bovine whole blood and will be labeled with CFSE and enriched with LArginine (L-A), ADP, and/or NG-Methyl-L-Arginine acetate salt (L-NMMA) and NO
donors like DPTA-NONOate. CFSE-labeled platelet-rich plasma (PRP) was perfused
through the micro channel under varying conditions. Micro channels were then imaged
using a florescence microscope and then processed with a MATLAB program to determine
percent surface area coverage.
Platelet agonists release Ca2+ from intracellular stores during platelet activation
plays a crucial role in regulating many platelet functions. Activation and inhibition
pathways of platelets trigger calcium stores in platelets [28][35]. eNOS-produced NO
requires Ca2+ entry for prolonged activation [36]. The process leading Ca2+ to increase
and decrease and its underlying mechanisms remain largely unknown, and the major Ca2+
sources for platelet activation and inhibition are not fully identified. To examine Ca2+
flux, platelets were loaded with the Fluo-4 Ca2+ ion indicators and fluorescence
waveform was monitored. Thus, our aim is to measure the elevations in [Ca2+] with
addition of exogenous and endogenous chemical agents to platelets loaded with Fluo-4
Ca2+ ion indicators where fluorescence waveform was monitored.
Therefore, the following hypotheses and specific aims have been generated to
fulfill this need.
1.8
The hypotheses of this study are:

Hypotheses
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Hypothesis 1: Percent surface area coverage of platelets will increase dosedependently when platelet derived activators (e.g., ADP) are included in the perfused
plasma but will be different on the upstream and downstream sides of thrombogenic
surface.
Hypothesis 2: Percent surface area coverage of platelets will decrease dosedependently when NO substrate L-Arginine is added endogenously to the perfused
plasma but will differ on the upstream and downstream sides of thrombogenic surface.
Hypothesis 3: Percent surface area coverage of platelets will decrease dosedependently when exogenous NO donor DPTA NONOate is added, as inhibitor, to the
perfused plasma but will differ on the upstream and downstream sides of thrombogenic
surface.
Hypothesis 4: Percent surface area coverage of platelets will increase for a given
plasma L-Arginine concentration as plasma ADP concentration increased. Likewise,
when for a given ADP concentration, platelet surface area coverage will decrease as LArginine concentration increases and will differ on the upstream and downstream sides of
thrombogenic surface.
Hypothesis 5: For a given amount of DPTA NONOate added to the PRP, platelet
surface area coverage will increase with increased plasma ADP concentration. Likewise,
for a given amount of ADP added to the plasma, platelet surface area coverage will
decrease and will differ on the upstream and downstream sides of thrombogenic surface.
Hypothesis 6: Plasma free platelets loaded with fluorescent Ca2+ indicators Fluo 4 will induce a dose-dependent rise in [Ca2+] with addition of an activator, ADP
indicating platelet activation through calcium signaling.
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Hypothesis 7: Addition of LA will decrease Ca2+ peaks, demonstrating the
immediate inhibition effect of NO synthase endogenously in ADP stimulated platelets.
Hypothesis 8: Addition of exogenous NO donor DPTA NONOate, with the intent
to overwhelm the endogenous feedback through platelet NO production, will decrease
[Ca2+] peaks.
1.9

Objectives

These hypotheses will be tested with the following methods:
1. A micro channel system will be created in which each channel is coated with
three isolated patches of fibrinogen, through a Xurography technique in such a
way that the channels can be exposed to flowing PRP under controlled shear
stresses.
2. In separate experiments, the individual agents ADP, L-Arginine, and DPTANONOate will be added to the PRP prior to injection through the channels, and
the amount of adhesion will be quantified as a function of the concentration of
each agent.
3. Combined concentrations of the three agents will be added to the PRP prior to
injection through the channels, and the amount of adhesion will be quantified as a
function of the ratios of concentrations of the agents.
4. Performing Calcium signaling experiments with platelet poor plasma loaded with
Fluo-4 Ca2+ ion indicators where fluorescence waveform was monitored to
measure is to measure the elevations in [Ca2+] with addition of exogenous and
endogenous chemical agents to platelets.

CHAPTER 2
BACKGROUND

2.1

Platelet Physiology

Platelets, known as thrombocytes, are small diameter, approximately 1-5µm.
They are present in larger number, about 150,000 to 400,000 per cubic millimeter of
blood, than white blood cells, but they occupy a smaller fraction of volume [37].
Platelets lack nuclei and have complex functions and metabolism. At resting state
platelets are irregular disc shaped structured bodies. Upon activation they undergo a
morphological changes, to a more spherical in shape with finger like extensions
(pseudopodia) [38]. The activated platelets have the increased surface area because of
their structure and act as an interconnecting mesh, entrapping fibrin fibers and other
platelets, forming a thrombus [39].
Platelets are primarily involved in hemostasis, preventing blood loss after injury,
with the formation of blood clots known as coagulation [40]. A platelet plug that clots
the blood at the site of injury is formed by an accumulation of the platelets on a fibrin
mesh with the help of the adhesive surface proteins on the platelet surface [41]. The
complicated wound repair process begins only when bleeding has stopped with clot.
Coagulation and wound healing release many factors that increase platelet aggregation,
mediate inflammation, and promote blood coagulation [42]. A low platelet count
(thrombocytopenia) leads to excessive bleeding and impairment of wound healing.
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However, a high platelet count (thrombocytosis) leads to formation of blood clots
(thrombosis) which can obstruct blood vessel and result in ischemic tissue damage such
as stroke, myocardial infarction, pulmonary embolism.
Platelets are in an inactivation state through normal circulation and become
activated at the sites of vascular injury [43]. The formation of blood clots is necessary to
save life from excessive bleeding upon injury and at the same time abnormal blood clots
formed in arteries can cause death. Thus, platelets play important role in both hemostasis
and thrombosis [44]. Platelets, after activation, release prothrombogenic substances that
amplify thrombus formation and inhibitory agents that control the extent of thrombus
formation. Platelets form a thrombus through adherence and aggregation [45].
2.2

Thrombogenic and Non-thrombogenic Regions

Atherosclerosis is an irregular pattern of platelets adhesion and thrombosis found
over the surface of lesions. Atherosclerotic lesion rupture leads to thrombus formation,
occlusion of the vessel lumen, and heart attack or stroke [7][46]. One mechanism of
sudden cardiac death is a coronary lesion in which plaque ruptures and causes a
thrombosis that occludes the vessel lumen [47]. Thrombus formation individually has
both spatial and temporal characteristics that consist of dynamic complex and diverse
biochemical, biophysical and biomechanical interactions [5]. This complexity increases
when multiple thrombi interact spatially and temporally [48]. The presence of functional
feedback loops (positive and negative), the variations in spatial and temporal relations in
flow, and biochemical reactions that activate and inhibit thrombus formation are
challenging to understand and predict [49]. Direct interactions between positive and
negative feedback mechanisms have not been extensively studied under flow conditions
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and are not tested with anticoagulated blood. It is expected that as platelet adhesion
grows locally on one thrombogenic region that is separated from another thrombogenic
region by a non-thrombogenic region, the agents secreted by the activated platelets will
influence adhesion on other thrombogenic region. Thus, to study such mechanisms,
platelet adhesion to thrombogenic regions patterned with different types of adhesive
proteins like collagen, fibrinogen, and albumin should be studied under the influence of
shear rates. The degree of platelet activation and inhibition by the addition of activators
and inhibitors on localized thrombogenic regions is needed.
Combined effects of positive and negative feedback signals acting at various
locations are the main controlling factors of the final thrombus size. To well explain
these effects, positive and negative feedback effects need to be examined on regions in
which thrombus formation is active next to regions in which thrombus is prevented. This
configuration allows examining the effects of platelet derived activators and inhibitors in
one region influences platelets in a different region under varying shear conditions. This
type of study requires spatially varying proteins surfaces coated with different proteins.
2.3

Fibrinogen

Platelet adhesion mechanisms are necessary to regulate the excessive bleeding or
reduce the blood loss at the sites of vascular injury and at the areas of circulation with
highest shear rates [50]. Platelet adhesion at the site of injury is needed to help thrombus
formation both in normal hemostasis and compulsive thrombosis [40]. Fibrinogen and
von Willebrand factor(vWF) mediate platelet adhesion. Fibrinogen, which is also called
factor I, plays important role in both platelet-surface and platelet-platelet interactions,
adhesion, and aggregation by binding to the glycoprotein (GP)IIb-IIIa receptor [40][51].
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In normal conditions, inactivated circulating platelets, do not interact with plasma
fibrinogen. At the site of vascular injury, platelet binding to vWF and collagen become
activated and release different agonists. This process triggers the exposure of the binding
site of fibrinogen on platelets, the activation depends on GPIIb/IIIa complex. GPIIb/IIIa
binds to fibrinogen, thus linking platelets to one another and to fibrinogen attached to the
vessel wall [52]. Fibrinogen is thus an important ligand for platelets adhesion to artificial
surfaces. Immobilization of fibrinogen on the surface of microchannels in the
microfluidic system helps in adhering inactivated platelets for studying their positive and
negative feedback effects on thrombogenic and non-thrombogenic regions.
2.4

DPTA NONOate

Exogenous NO donors are pharmacological compounds that release NO instantly,
are used widely in cardiovascular physiology and therapeutics [25][26] to evaluate the
role of NO in platelet Ca2+ signaling and its functions. DPTA NONOate is the most
available exogenous NO donor with high diffusion coefficient of NO and consequence of
its small size has a significant role in inhibiting activated platelets. DPTA NONOate are
converted to NO and could replace deficient levels of NO in patients with CAD.
Replacement with exogenous NO donors is helpful in patients with the impaired activity
of the endothelial L-Arginine-NO pathway. DPTA NONOate spontaneously dissociates
NO with a half-life of three hours at 37oC and five hours at 22-25oC, Ph 7.4.
The replacement of endogenous NO by exogenous NO donors like DPTA
NONOate in platelet pathobiology has become great foundation in the field of
cardiovascular medicine [27]. Our aim is to study how exogenous NO donors modulate
the bioactivity of endogenously produced NO in platelets.
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2.5

Shear Rates

Hemodynamic shear forces have been reported to exert direct and indirect effects
on platelet reactivity. Shear forces activate platelets leading to spontaneous or facilitated
aggregation in vitro and stimulate the production of endothelium-derived antiaggregatory agents. Experiments done in our lab previously by Adams and Sanakam
have shown that shear rate affects the degree of adhesion and aggregation of platelets in
microchannels [33][34]. A microfluidic system was constructed to simulate the flow of
blood near the vessel wall, including shear forces and their effect on platelet activation
and adhesion. Many issues should be considered when studying the flow properties of
blood or plasma. Whole blood is well known to behave like a non-Newtonian fluid, with
the apparent viscosity decreasing with increasing shear rate. At higher shear rates, whole
blood approaches a constant viscosity. The major contributor to the non-Newtonian
behavior of whole blood is the formation of rouleaux, or clusters of red blood cells at low
shear rates. The plasma itself is less subject to non-Newtonian effects. Therefore, in the
current studies, plasma is assumed to behave as a Newtonian fluid with a constant
viscosity of 1.2 cP at body temperature (37 °C).
Platelet adhesion and aggregation cause the arrest of bleeding at vascular injury,
but they can also cause arterial occlusion at sites of atherosclerosis, complicating
cardiovascular diseases [49][53]. Shear rates in flowing blood typically range from 5001600 s-1 for arterioles, from 300-800 s-1 for large arteries, and from 800-10,100 s-1 for
atherosclerotic stenosed arteries [54]. The shear rate at the vessel wall plays an important
role and is of great interest in biological processes, including normal physiologic
signaling and the pathophysiology of atherosclerosis and thrombosis [55]. The height of
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thrombi increases linearly with the increase in wall shear rates and has a denser shell for
higher wall shear rates. Platelet buildup is caused by shear rates and the separation by the
dynamic force of flow [56]. Study of shear rates provide a different insights of thrombus
formation and suggests valuable elucidations for certain clinical physio pathological
phenomena, including hemostasis and pathological thrombosis.
2.6

Devices for the Study of Platelet Adhesion

Kantak et al. used a PDMS stamp impression technique (micro molding) to
pattern proteins within a channel [57]. They used LbL (layer-by-layer) process to coat
the stamp with the protein of interest and were then pressed on to the patterned surfaces
in channels. PDMS channels allow protein absorption and are optically clear, which
allows platelet adhesion imaging optically through the material. PRP extracted from
bovine blood was injected into the channels. Platelets were then labeled with acridine
orange (AO). The layered proteins were examined through fluorescent tagging. The
flow rate of PRP was controlled by varying fluid shear rate. They indicated that the
effects of agonists already present in sample were not accounted for, and they specified
the need to form thrombogenic regions to study the role of agents in the inhibition and
activation of platelets [57][58][59].
Eshaq used a system that consists of a silicone gasket sandwiched between two
Plexiglas blocks with different concentrations of agonists that are produced by platelets
after their activation [8]. Channels were cut into the elastomer and the inlet and outlet
holes were drilled in the upper Plexiglass plate with fibrinogen coated on to a surface
through LbL with PDDA and PSS as polyion. She found that platelet behavior varies
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with local concentrations of activating and inhibiting agonists such as ADP and LArginine [8][13][14][60].
Watson and Lopez used methods like those used by Eshaq but did not use the
same plastic substrate from the elastomer for the LbL processes because as it was not
suitable, instead they used glass slides. The AO staining process used lead to nonspecific
staining of the surface where surface became stained without subjecting it to platelets
indicating false staining. To solve this problem, Lopez introduced a dynamic LbL
process which is similar to the standard static LbL process, except the fluid in contact
with the surface during layering is in motion. He observed that this surface provides
more accurate fluorescence-based estimates of platelet surface coverage [61][62].
Sanakam and Adams repeated the protocols used by Lopez and Watson, but with
fibrinogen patterned into patches on the glass slide. They used FITC tagging, to screen
the fibrinogen patches unlike the previous studies where PRP was passed through the
channels and stained with AO. Their primary research goal was to develop a
thrombogenic region surrounded by non-thrombogenic region which would not degrade
the fibrinogen surface and would prevent non-specific adhesion of platelets outside of the
fibrinogen patches. Therefore, they designed a channel with distinct thrombogenic and
non-thrombogenic regions. Xurography was used to make patterns of the thrombogenic
and non-thrombogenic regions to produce micro channel. Their work studied fibrinogen
only. The study of other proteins that affect platelet adhesion was not practical, because
the experiments were time consuming and most of the process had to be done on the
same day itself [33][34].
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Therefore, the fluid model we proposed used the protocols and micro channel
designed by Sanakam and Adams to pattern the protein surfaces of fibrinogen. The
platelet adhesion and platelet activation depend on multiple activators and inhibitors that
are derived from platelets themselves. Hence the proposed model was used to study
combined effects of positive and negative feedback in platelet adhesion by adding
platelet-derived activators and inhibitors to platelets adhered on different surface protein
fibrinogen.
The experiments reported here are extension of the work done by Sanakam and
Adams. Sanakam and Adams built a micro channel patterned with thrombogenic regions
and non-thrombogenic region (one that has thrombogenic and non-thrombogenic surfaces
side-by-side) to study simultaneous examination of positive and negative feedback effects
on regions in which thrombus formation is active next to regions in which thrombus is
prevented and got few results which suggests an influence of agents secreted by upstream
platelets on downstream adhesion, but some of the results were not statistically
significant; additional data was necessary to quantitatively model the effects. Combined
effects of positive and negative feedback signals acting at various locations are the main
controlling factors of the final thrombus size. Sanakam and Adams did not concentrate
on the combined effects of chemical agents and neglected the percent surface area
coverage and its effects when production of NO is prevented with the addition of ADP to
the plasma along a thrombogenic surfaces. This will be used to test various strategies to
inhibit thrombus formation under flow conditions and to minimize the impact on
hemostasis.

CHAPTER 3
METHODS

3.1

Experimental Process for Microchannels

To evaluate the adhesion of platelets, a system was used in which micro channels
were created with Xurography and patterned on the bottom surface with an isolated
thrombogenic fibrinogen region surrounded by a non-thrombogenic region. Platelets
were extracted from bovine whole blood and were labeled with CFSE. The CFSElabeled PRP was perfused through the micro channel under varying conditions. Micro
channels were then imaged under a florescence microscope and the images were
processed with a MATLAB program to determine percent surface area coverage. This
procedure was repeated in under various experiments with a varying combinations of
activator ad inhibitor concentrations under the influence of shear rate.
The flow system is shown in Figure 3-1. A syringe pump was used to drive the
CFSE-labeled PRP flow into the micro channels. The flow rate and shear rate were
controlled using the control panel of the syringe pump.
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Figure 3-1: Experimental set up for the microchannel flow system.

3.2
3.2.1

Chemicals Used for Both the Protocols

Chemical Preparation
To prepare PBS solution, one packet of PBS (Sigma Aldrich-P3688) was

dissolved into 1000 mL of DI water to make a bulk solution. Then bulk solution was
stored in the refrigerator until used. Bulk PBS, when used, was poured from into
individual 50 mL styrene tubes as to not contaminate the bulk solution.
To prepare CFSE solution, 500 µg CFSE per vial (Sigma Aldrich-21888), 60 µl
of dimethyl sulfoxide (DMSO, Sigma Aldrich-276855) was added using a pipet to give a
stock solution of 14.9 µM. This solution was prepared immediately before use and used
completely each time. Alternatively, 25 mg CFSE was added to 3 mL DMSO to give a
final stock solution of 14.9 µM. The solution was aliquoted at 60 µl and stored in the
freezer to be thawed just before use.
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To prepare a 20 mM CaCl2 solution, 444 mg CaCl2 (Sigma Aldrich-C1016) was
added to 200 mL of DI water. The solution was stored at 4 ºC.
A BSA packet (Sigma Aldrich-P3688) at pH 7.4 was divided up evenly into 14
tubes and stored in the freezer until used. Just before use, each tube was dissolved into
35 mL of DI water to produce a 2% solution.
One tablet of tris buffer saline (Sigma Aldrich-T5030) was added to 37.5 mL DI
water and vortexed until the tablet is dissolved. This procedure was repeated 12 times to
produce 450 mL tris buffer saline solution. The solution was stored in the refrigerator
until used.
Fibrinogen was added to the tris buffer solution in a 2:1 ratio. Stock solution was
made by adding 80 mg of fibrinogen (Sigma Aldrich-F8630) to 40 mL of tris buffer
solution. The solution was stored in the refrigerator until used.
Four mL of DI water was added to 25 mg of L NMMA in the original bottle and
mixed to remove all the L NMMA. The bottle was added to 95 mL of DI water to form a
1 mM solution. The solution was stored at room temperature.
Twenty mL of Di water and 34.8 mg of L-A powder (Sigma Aldrich-A5006) were
combined to form a 10 mM stock solution. This solution was diluted by adding 5 mL of
the stock solution to 45 mL of DI water in a 50 mL tube. The dilute solution was filtered
with a 0.45 m syringe filter. Solutions were stored at room temperature
DPTA NONOate (Cayman Chemical-825110) was prepared by adding 5.74 mg in
30 ml of 0.01 M NaOH (Fluka Chemika-53339) solution to make it 1 mM stock solution.
Alkaline solutions of NONOate in 0.01 M NaOH are stable and stored at 0 °C for 24
hours. The half-life of DPTA NONOate is 5 hours at 22O °C and pH 7.4.
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Five ml of PBS and to 2.1 mg of ADP (Sigma Aldrich-A2754) were added and
mixed to form a 1 mM stock solution. The solution is stable when stored at 70 °C. ADP
was incubated for 15 minutes after adding it to PRP and then perfused through the
microchannels.
3.2.2

Bovine Blood Source
Bovine blood was collected from Louisiana Tech University Farm located in

Ruston. Blood was withdrawn from a puncture wound made by a 16-gauge needle. The
blood was collected in a polystyrene tube that was prefilled with sodium citrate, a
calcium chelator, in the ratio of 9:1 by volume i.e., nine parts of blood to one part citrate.
Sodium citrate was prepared by adding 16.17 grams of trisodium citrate dihydrate from
Sigma Aldrich in 500 ml of deionized water to make it to final concentration of 0.1 M. In
addition to binding calcium, citrate helps to maintain the pH value of the blood.
3.2.3

Preparation of PRP
To each 15 ml tube, 4 ml of blood was added and centrifuged at 1500 rpm for 10

minutes. The serum and buffy coat (PRP) from the top of RBC layer was removed and
placed in a clean Eppendorf tube. To remove the remaining RBC’s, the tube was
centrifuged again at 1500 rpm for 3 minutes at 25oC. After removing the left-over
RBC’s, the PRP was transferred into a clean tube and centrifuged again at 2700 rpm for
10 minutes, forming a platelet pellet. The separated platelet poor plasma (PPP) and
platelet pellet were saved in a fresh clean tubes.
3.2.4

CFSE-Labelled PRP
Carboxyfluorescein succinimidyl ester (CFSE) is an ester compound that

passes through the membrane of viable cells and cleaved by intracellular esterase to form
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fluorescent compound that can be passively injected into the platelets due to its negative
charge [63]. Fluorescein derived from CFSE has an amine-reactive succinimidyl group
that can covalently bind to proteins or other amino groups in the cell or on its membrane.
This covalently attached fluorescein can be analyzed over several weeks [64]. PBS was
added to isolated platelet pellet to bring the final volume to 6 ml. 60 mL of CFSE were
added and incubated in the dark at room temperature for 10 minutes. It was then
centrifuged at 2,600 RPM for 10 minutes. The supernatant was disposed of, and the
platelet pellet resuspended into 2 mL of PBS. The isolated PPP was added to the CFSElabeled platelets and PBS was added to give a final volume of 4 milli Liters.
3.2.5

Preparation of Microchannels
The microchannel system (Figure 3-2) includes a silane bottom slide and quartz

glass slide top slide. Kapton tape (Kaptonetape-PPTDE-2, Double sided polymide tape2’’ X 36 yds) is cut with a rectangular slit that forms the channel and is sandwiched
between the two slides. Two holes were drilled in the quarts slide, and pipette tips were
glued to them to provide fluid inlet and outlet ports.

Figure 3-2: The microchannel with inlet and outlet flow units.

26
3.2.6

Silane Slide Preparation
The silane slides were cleaned with Alconox and dried with nitrogen gas. A

Graphtec Craft Robo was used to separate the tape into three regions, A, B, and C, as
shown in Figure 3-3. Region A is outside of the flow area. Regions B and C are inside
the flow area. Region B is to be coated with a non-thrombogenic protein, and Region C
is to be coated with a thrombogenic protein. The Kapton tape was removed from region
B and incubated with bovine serum albumen (BSA) for two hours to block platelet
adhesion on that region; because the silane glass slide surface is hydrophilic, it adsorbs
the BSA. Upon removal from the BSA, slides were rinsed gently with DI water and dried
with nitrogen gas. The outlines of the regions three 2 mm by 2 mm islands, labeled C
were marked with a permanent marker on the back of the slide, and the tape was then
removed from these regions.

Figure 3-3: Slide with the pre-cut Kapton tape pattern.

Fibrinogen was added with a pipet to these regions, without crossing the outline
marked in permanent marker and incubated for one hour. In the final slide the region
labeled B was non-thrombogenic (covered with albumen), the regions labeled A were
thrombogenic, and the rest of the slide remained covered with Kapton tape as shown in
Figure 3-4.
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Figure 3-4: Silane Slide patterned with thrombogenic region (green) and non-thrombogenic
region (gray).

3.2.7

Quartz Glass Slide Preparation
The plain quartz glass slide was used as the top of the channel. Inlet and outlet

holes were cut into the top slide using a DREMEL rotary tool.
3.2.8

Microchannel Fabrication
Each coated Silane slide was used for the base of the channel. The Kapton two-

sided tape channel pattern was placed firmly onto the top slide. The plastic covering was
removed from the tape and the base slide was pressed firmly on to the tape. The
microchannel was placed into a vice and pressed for 10 minutes to bond the channel top
and base slides together. Inlet and outlet tubing with inside diameter of 0.091” was
attached to the top slide using UV glue.
3.3

Perfusion of PRP through the Channels

The syringe pump (Manufacturer – BD, Ref # 309604) drove the PRP through the
micro channels at a specific constant flow rate. The flow rates 𝑄 were calculated from
the equation for Couette flow 𝑄 = 𝑤ℎ2 𝛾𝑤 /3 where 𝑤 is the width of the channel and ℎ is
the height of the channel, 𝛾 is the shear rate at the wall [65]. After the PRP is perfused
through microchannel, PBS is used to rinse the remaining PRP out of the channel at
1/10th of the plasma perfusion shear rate.
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3.4

Mathematical Modeling of PRP Flow in Micro Channels

The most common forces related to platelet adhesion studies are shear stress, 𝜏,
measured in dynes/cm2 and shear rate, 𝛾, s-1. Shear stress is defined as the force per unit
area exerted in the direction of the flow.
Shear stress can be expressed as
 = −µ

𝑑𝑣𝑧
𝑑𝑟

Equation 3-1

where µ is the viscosity and 𝑑𝑣/𝑑𝑟 is the local velocity gradient or shear rate. Or, since
𝛾 = 𝑑𝑣𝑧 /𝑑𝑟,
𝑤 = 𝜇𝛾,

Equation 3-2

and shear stress near the wall of tubular vessels (e.g., the tubes leading to the
microchannel) is expressed as function of the volumetric flow rate 𝑄, for which
=

4µ𝑄
𝜋𝑟 3

The flow of PRP in micro channels is modeled as the PRP flow between two
fixed parallel plates as illustrated in Figure 3-6.

Figure 3-5: Flow between two fixed parallel plates.

From the above model, we can assume Couette flow, where the following equation apply
𝑄=
and

2𝑢max ℎ𝑤
3

Equation 3-3
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𝑤 =

2µ𝑢max
ℎ

Equation 3-4

hence from Equations 3-2 through 3-4,
𝑤ℎ2 𝛾𝑤
𝑄=
,
3
where, 𝑤 is the width of the micro channel and ℎ is the half the height of micro channel.
3.5

Addition of Activators and Inhibitors

Adding activators and inhibitors modulates the extent of platelet adhesion. The
activator ADP (Sigma-Aldrich) was added to PRP before the experiment and incubated
for 10 mins. The inhibitors, L-Arginine and DPTA NONOate were also added to PRP to
test the effect of inhibitors on platelets. Ca2+ is used as an indicator for platelets
activation and will be added for the activation of platelets. Therefore, CaCl2 is added for
recalcification of PRP before perfusing PRP into micro channel along with activators and
inhibitors.
3.5.1

Effects of ADP and NO on Platelets
The aim of the first set of experiments was to test the effect of various

concentrations of ADP and NO on platelet adhesion and aggregation. The project was
divided in to three parts.
First, the effect of NO on platelet adhesion to fibrinogen-coated microchannel
with thrombogenic and non-thrombogenic regions on it was studied. This study used two
methods of nitric oxide production, one endogenous and one exogenous. Endogenous
production that was enabled by the addition of L-Arginine, a precursor for NO production
through NOS. Exogenous production was enabled by the addition of the NO donor
DPTA NONOate to the CFSE-labelled PRP.
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The second part of the project examined the effect of ADP alone on platelets
adhesion. ADP was added to PRP at different concentrations and incubated for 15
minutes.
For the third part of the project, the combined effect of ADP and NO was
examined. Both ADP and L-Arginine or DPTA NONOate were added to the PRP before
it was perfused in the microchannels. For each of three concentrations of ADP, 2 µM, 5
µM, and 10 µM, three concentrations of LA were used, 5 µM, 10 µM, and 15 µM. The
same concentrations of ATP were combined with 5 µM, 10 µM, and 15 µM of DPTANONOate.
3.6

Syringe Filling

Each syringe was filled based on the experiment in the order below and then
secured into the syringe pump.

31
Table 3-1: Summary of Parameters used in experiments.
PRP (mL)

CaCl2 (L)

ADP (𝛍𝐋)

L-A (L)

Incubation for
15 minutes
3

400

DPTA
NONOate
(L)

0
6
15
30

3

400

0
15
30
45

3

400

0
15
30
45

3

3

400

400

0

0

6

15

15

30

30

45

0

0

6

15

15

30

30

45

CaCl2 was added to recalcify the PRP because Ca2+ is a known indicator of
platelet activation and therefore necessary for the activation of platelets. After perfusion
of CFSE labeled PRP, the inlets and outlets of the microchannels were removed,
including glue, and washed with Alconox soap and left it to dry for 5 minutes.

32
3.7

Calculation of NO Concentration from an NO Donor

We have used DPTA NONOate, an exogenous NO donors in this work with halflife of about 5 hours. While the exact concentration of NO can be measured via the
electrochemical probes and can be deduced from the Nitrate/Nitrite assay, it is useful to
have a mathematical model for the NO concentration in the solution as a function of time.
Assuming that the donor and NO both decay exponentially in time and that the half-life
for NO is much shorter than that for the donor, a balance of production and decay of NO
yields the simple equation:
[𝑁𝑂] =

𝜏𝑁𝑂
𝜏𝐷

[𝐷0 ]𝑒 −𝑡⁄𝜏𝐷

Equation 3-5

where [NO] is NO concentration, [D0] is the initial donor concentration, and  NO and  D
are the exponential decay times (proportional to the half-life) for NO and the donor,
respectively. For a given a NO donor, DPTA NONOate with a half-life of 5 hours, the
initial NO concentration will be approximately 0.54 x 10-3 times the initial donor
concentration (millimolar concentrations of donor yield nanomolar concentrations of NO.
The expected concentration of NO, for the given the concentrations of 5, 10, and 15µM
DPTA NONOate were 2.7, 5.4, and 8.1nM respectively which were greater than the
minimum NO concentration required to inhibit platelets under all conditions that is
0.15nM [66].
3.8

Fluorescent Microscopy

Olympus 1X51 fluorescent microscope was used to image the thrombogenic and
non-thrombogenic regions of interest at a magnification of 20X, and FITC and TRITC
filters. The regions imaged are shown in Figure 3-6. Regions T1, T2 and, T3, in the
direction of flow, were the 2 mm by 2 mm dots on the silane slide. Regions NT1 and
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NT2, from upstream to downstream, were the two non-thrombogenic regions. The
images from each experiment were saved and processed through the MATLAB image
processing program to calculate the percent surface area coverage.

Figure 3-6: Nomenclature for the images takem from the slide.

3.9

Experimental Process for Calcium Imaging

Calcium concentration is very low (~100 nM) in the cytosol of a cell and is highly
concentrated (~2 mM) at intracellular calcium stores such as endoplasmic reticulum (ER)
and extracellular spaces creating a difference in calcium concentration which is
effectively utilized to deliver signals across the cell membrane. This implies that
activating calcium signaling with any stimulus leads to release of calcium from these
stores following increase in calcium concentration of cytosol. The calcium released in
the cytosol is either actively taken up by the ER via calcium channels called SarcoEndoplasmic reticulum Ca2+-ATPase (SERCA) or it is flushed out through calcium
channels present in plasma membrane. During these processes, calcium transients/spikes
are formed, which are characterized by the rise and fall of calcium concentrations in the
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cytosol repeatedly. Experiments were performed to monitor changes in cytosolic calcium
level in platelets that were loaded with a calcium-sensitive fluorophore Fluo-4 AM.
Fluo-4 AM is a cell permeant variant of Ca2+ indicator which increases the fluorescence
intensity upon binding to calcium.
3.9.1

Chemicals Used in Calcium Signaling in Platelets

Calcium indicator dye, Fluo-4 AM, was obtained from Invitrogen and used in calcium
imaging experiments. Locke’s solution used here was prepared in the Dr. Decoster’s lab
following Locke’s protocol. All agonists and other chemical agents used in experiments
were bought in powder form (Sigma) except exogenous NO donor DPTA NONOate,
which was brought from Cayman Chemical. Preparation methods were given in Section
3.2. Ionomycin (Iono) is the calcium ionophore that facilitates the movement of calcium
in and out of the cells, is used as a positive control for calcium influx in the cells.
3.9.2

Platelet Extraction
Platelets were separated from bovine blood brought from Louisiana Tech Farm

using centrifuge method. The extracted platelet pellet was suspended in 4 ml of PBS.
3.9.3

Treating Platelets with Calcium Ion Indicators
The collected platelets in PBS were treated with Fluo-4 calcium ion indicator and

then the solution was allowed to settle down inside the incubator at 5% of CO2 and 37 oC
for about 15-20 mins. Loading solution (Lock solution) of 3 ml with 3 µl of pluronic
acid with 5 µl of Fluo4 calcium indicator was added and incubated for 1 hr. Later, 500 µl
of recovery solution was added to each of three wells and incubated for 45 mins. Then
we removed the recovery solution from each well expecting at least platelets settled at the
bottom of the well.
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3.9.4

Calcium Activity in Platelets with Platelet Activators and Inhibitors.
The objective of these experiments was to see how platelet activators and

inhibitors affect the calcium activity in platelets. Platelets were treated with an activator
ADP, exogenous NO donor, DPTA NONOate, and L-Arginine, which acts as
endogenous NO donor, in the presence external calcium.
3.9.5

Calcium Imaging After Treatment with Chemical Agents
The cells were imaged after the recovery period while being stimulated with

ADP, and ionomycin to induce calcium signaling. Chemicals L-Arginine and DPTA
NONOate were added after stimulating platelets with ADP. Fluorescent intensity
changes in the cells in real-time, which corresponds to the calcium influx due to
stimulation via agonist, was imaged and recorded in real-time under the inverted
microscope (Olympus CKX41) with a 488 nm excitation wavelength filter at a frame rate
of 4 seconds. The experiment was visualized and recorded in the Intracellular Imaging
software (InCyt Im™ Imaging system, Version 5.29e, Cincinnati, OH).
After treating platelets with ADP/L-A/DPTA NONOate, there was a small
dilution artefact observed, where the calcium peak goes down and comes back to its base
position with increase in fluorescent intensity with respect to the agonists added. These
artefacts which shows small decrease in fluorescent intensity and accounts to fall in
calcium peaks were corrected by analyzing the results for all the cells that showed
calcium response above the normalized threshold fluorescence values i.e., 1.2 or 20%
above baseline for all agonist stimulations.
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3.9.6

Measuring and Analyzing Calcium Fluorescence Intensity
The recorded experiments were analyzed in InCyt Im™ Imaging System software

set up in Dr. DeCoster’s lab. Regions of interests (ROIs) termed as ‘Trial’ in the graphs
obtained from the experiments and were created as a circle around each cell identified in
a frame. ROIs with maximum fluorescence caused by ADP stimulation were selected to
maximize the visualization and analysis of the number of cells in the frame. The
fluorescence intensity of each cell over time were measured for the ROIs selected and the
data obtained were then normalized to their starting values (baseline) in Microsoft
Excels. The normalized values of fluorescence intensity over time are represented by line
graphs and are used to compare cells within the experiment or to other experiments. The
averages of peak fluorescence intensity were calculated for each experiment, and the
values were averaged over 3 experiments.
3.10

Statistical Analysis

The single factor Analysis of Variance (One-way ANOVA) was performed to
analyze the effect of different concentrations of ADP/L-A/DPTA NONOate on overall
PSAC of the microchannel and two factor Analysis of Variance (Two-way ANOVA) was
performed to analyze the effect of PSAC for different concentration of ADP/L-A/DPTA
on three different thrombogenic regions T1, T2, and T3 respectively. A 95% confidence
interval and corresponding α = 0.05 threshold was used. If the P values for the test is less
than the α = 0.05 it means that F-statistic value is very large, higher than the critical value
indicating that the null hypothesis for single factor ANOVA, the means of overall PSAC
for three concentration of agonist (5, 10, and 15 µM) are same, is rejected.
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The two factor ANOVA was performed to analyze the effect of PSAC on
microchannels by two factors, one of them was the thrombogenic regions from upstream
to downstream (T1, T2, and T3) and the other factor was the ADP/L-A/DPTA NONOate
concentrations (2, 5, and 10M). The three-null hypothesis for two-way ANOVA were
the means of PSAC grouped by one factor (different thrombogenic regions T1, T2, and
T3) are same and the means of PSAC grouped by another factor (different concentrations
of chemical agents) are same and that there exists no interaction between two factors for
the α = 0.05 level. This help us to analyze if there is a any significant difference in the
adhesion characteristics among different thrombogenic regions with release of
antagonists with different concentrations. If the p values for three null hypothesis for the
test are less than the α = 0.05 indicates that there is statistical difference in means of
PSAC for thrombogenic regions T1, T2, and T3 and for different concentrations of
chemical agent and says there exists interaction between two factors and depends on each
other for the α = 0.05 level. A logarithmic transformation was used to determine the
statistical difference between the small values on the non-thrombogenic regions against
the larger values on the thrombogenic regions, because the large standard deviation in the
case of the thrombogenic region is too large to rule out zero as a mean, even though all
values are above zero and substantially larger than all the values on the nonthrombogenic region [67].

CHAPTER 4
RESULTS

4.1

Platelet Surface Area Coverage

Images from thrombogenic and non- thrombogenic regions of the microchannel
after perfusion of CFSE-labeled platelets with no chemicals at a shear rate 1500 s-1 were
collected and processed through the MATLAB program to calculate the percent surface
area coverage. Figure 4-1 shows sample images of thrombogenic and nonthrombogenic regions of the microchannel (Region A and B) as identified in Figure 3-6.

Figure 4-1: Overall adhesion of platelets from upstream to downstream regions of the
microchannel.

Green portions on these images that were above a threshold intensity value of 30
were extracted and represented as white areas, while the other regions were represented
with black in binary images, as shown in Figure 4-2. Image A in Figure 4-2 shows
platelets adhered to fibrinogen patterned on thrombogenic region of the base slide after
38
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perfusion CFSE-labeled platelets and Image B was its binary image. The overall percent
surface coverage of Image B (white area divided by total area times 100) is 0.89.

Figure 4-2: Image A is first image of region T1 from the base slide perfused with CFSE
labeled platelets with no chemical at a shear rate of 1500 s-1. A) Original image, B) Binary
Image.

Figure 4-3 is another image, where most of the entire surface (62.2%) is covered
with green florescence. The binary image with the white color as shown in Image B.

Figure 4-3: Sample Image from the base slides, with no chemical added, perfused with CFSE
labeled platelets at a shear rate of 1500 s-1. Overall average percent surface coverage is 62.2.
A) Unprocessed image B) Binary of Image A.

Figure 4-4 is another image, where the florescence image surface is covered
except for a region at the left side of the image. The surface coverage is 93.35%.
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Figure 4-4: Image from the base slides, with no chemical added, perfused with CSFE labeled
platelets at a shear rate of 1500 s 1. Overall average percent surface coverage is 93.0 A)
Original image, B) Binary of Image A.

The non-thrombogenic region was imaged in FITC to show the BSA surface and
fibrinogen regions. Figure 4-5 shows contrast between the two regions where fibrinogen
regions surrounded by BSA adhered to silane slide surface. Image A represents the
region covering T1, on the left, and NT1, on the right, and Image B is the region covering
T2, on the left, and NT2, on the right, of the sample base slide.

Figure 4-5: Slide imaged in FITC after addition of the fibrinogen. The tagged fibrinogen
(green) is to the left, and the blocked BSA (black) region is to the right for both image A
(Region covering NT1 and T2) and image B (region covering NT2 and T3).

Different concentrations of exogenous and endogenous chemical agents with
shear rate of 100 s-1 on 5 mm channel width and 2 mm by 2 mm of thrombogenic region
size were investigated in these experiments. Different samples of blood (collected from
the same animal on different days) were used to study the combined effects of positive
and negative feedback on micro channel. Based on the initial experiments the
concentrations 0, 5,10, and 15 µM of LA and DPTA NONOate with 0, 2, 5, and 10 µM
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were used in the experiments. For each experimental trial, different samples of blood
were used to determine the effects of chemical agents. Three sets of experiments for each
effect were completed to test each hypothesis.
4.2

Experiment Controls

Our key criteria in designing microchannel was that fibrinogen and platelets
should not bind to the non-thrombogenic regions. BSA was selected as blocking agent in
creating non-thrombogenic regions because it effectively blocks the binding of both
fibrinogen and platelets to the silane slide. It was also necessary to verify the BSA,
untagged fibrinogen, untagged platelets do not show florescence and need to ensure that
FITC signal was specific to CFSE-labeled platelets. Figure 4-6 shows images were
taken of the silane slide under an FITC filter at each step of process during experiments,
before addition of BSA, after addition of BSA, after addition of fibrinogen, and after
perfusion of labeled and unlabeled PRP. The images showed no fluorescence within the
fibrinogen regions.

Figure 4-6: Images of the fibrinogen regions at each step of the experimental process. Image
A: blank slide. Image B: after addition of BSA. Image C: after addition of untagged
fibrinogen. Image D: after perfusion with unlabeled PRP.

Images of non-thrombogenic region, the region surrounding the thrombogenic
regions showed little to no florescence after perfusion with CFSE-labeled platelets,
verifying their non-thrombogenicity (Figure 4-7).
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Figure 4-7: Control images of non-thrombogenic regions after perfusion of channels with CFSE
labelled platelets, as recorded from four different experiments. Image A: No Chemical Added,
Image B: ADP added, Image C: L A added, Image D: DPTA NONOate.

Images of non-thrombogenic regions also showed florescence only when the
coated fibrinogen was outside the thrombogenic region and the non-thrombogenic region.
This problem occurred because of inaccuracy in coating fibrinogen on 2 mm by 2 mm
thrombogenic patches that had been covered by Kapton tape and manually marked with a
Sharpie. Sample images are shown in the Figure 4-8.

Figure 4-8: Sample images from non-thrombogenic regions (Images A & B are from NT1;
Images C and D from NT2) when fibrinogen is outside of the marked region.

4.3

Effect of ADP Concentrations on Platelet Surface Area Coverage

ADP is a well-known activator that enhances contact-induced activation of
platelets. ADP in concentrations of 2, 5, and 10 µM was added to CFSE-labeled PRP
consecutively according to the protocol described in the methods section. The CFSElabeled PRP was perfused through microchannels at a constant shear rate of 1500 s-1.
Fluorescent images of the microchannels were collected for each ADP concentration and
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repeated at least three times at constant shear rate to see the good amount of platelet
adhesion to the thrombogenic regions patterned with fibrinogen.
The collected fluorescent images were processed using MATLAB code to see the
percentage surface area coverage (PSAC). Sample fluorescent images of the
microchannels, after perfusion CFSE-labeled PRP, are shown in Figure 4-9. The base
slides were perfused with CFSE-labeled platelets with different concentrations of ADP
(0, 2, 5, and 10 m, from top to bottom row) at a shear rate 1500 s-1. The three
thrombogenic regions are upstream (T1), middle (T2), and downstream (T3). Nonthrombogenic region NT1 is between regions T1 and T2, and non-thrombogenic region
NT2 is between regions T2 and T3. Both platelet adhesion and thrombus size increased
with increased ADP concentration. The PSAC averaged over the three thrombogenic
regions for each ADP concentration is shown in Figure 4-10. The error bars represent
the standard deviation over all trials and all three regions. The charts in this dissertation
used logarithmic scale. These results were consistent with the acceleration of platelet
recruitment by ADP.
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Figure 4-9: Platelet adhesion under different concentrations of ADP 0, 2, 5 and, 10 µM/L in
first, second, third and, fourth row, respectively. Images T1, NT1, T2, NT2, and T3 in each row
represents nomenclature for the images takem from the slide as mentioned in Figure 4-1 and
Figure 3-6.
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Figure 4-10: Experimental results on overall percent surface area coverage with no
chemical, 2 µM/L ADP, 5 µM/L ADP, 10 µM/L ADP added perfused at a shear rate of 1500
s-1. Error bars represent standard deviation.

Figure 4-11 shows platelet adhesion at different concentrations of ADP from
upstream to downstream. The PSAC is shown on a logarithmic scale to allow the small
values on the non-thrombogenic regions to be plotted along with the larger values on the
thrombogenic regions. Except for the case of10 μM, adhiesion increases from T1 to T2
and then decreases at T3. Fluorescence on NT1 and NT2 was minimal. For the 10 µM
PSAC increased monotonically from upstream to downstream.
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Figure 4-11: Experimental results on effect of percent surface area coverage for different
concentration of ADP on microchannel from upstream to downstream say T1-NT1-T2-NT2.
Error bars represent standard deviation.

4.3.1

Statistics
The ANOVA single factor and two factor test analysis was performed to analyze

the effect of different concentrations of ADP on overall PSAC and to analyze the effect
of PSAC for different concentration of ADP on microchannel from upstream to
downstream on three different thrombogenic regions T1, T2, and T3 respectively. The
single factor analysis of variance shows the statistical significance difference between the
means of overall PSAC for three different concentration of ADP 2, 5, and 10M. The P
values for the test was 0.000315 which is less than the α = 0.05 it means that F-statistic
value is very large, higher than the critical value indicating that the null hypothesis for
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single factor ANOVA is rejected. This p value suggested a significant difference in the
adhesion characteristics among ADP concentrations.
The two factor ANOVA was performed to analyze the effect of PSAC on
microchannels by two factors, one of them was the thrombogenic regions from upstream
to downstream (T1, T2, and T3) and the other factor was the ADP concentrations (2, 5,
and 10M). The p values for three null hypothesis are 0.002, 0.000000426, and 0.03
indicating that there is statistical difference in means of PSAC for thrombogenic regions
T1, T2, and T3 and for different concentrations of ADP 2, 5, and 10M and says there
exists interaction between two factors and depends on each other for the α = 0.05 level.
This led us to believe that there is a significant difference in the adhesion characteristics
among different thrombogenic regions with release of agonists and their concentrations.
4.4

Effect of L-Arginine on PSAC

L-A was added to the CFSE-labeled PRP in four concentrations (0, 5, 10, and 15
𝜇𝑀) before perfusion through the microchannel at a shear rate of 1500 s-1. Figure 4-13 is
a montage of sample images of the microchannel base slide from this study. The
columns from left to right are regions T1, NT1, T2, NT2, and T3. L-A concentrations are
0 µM (first row), 5 µM (second row), 10 µM (third row), and 15 µM (fourth row).
Adhesion is easily seen in the 5 µM images and becomes sparse at all locations at 10 and
15 µM concentrations.
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Figure 4-12: Platelet adhesion under different concentrations of L-A 5,10 and, 15 µM/L in
first, second, third and, fourth row, respectively. Images T1, NT1, T2, NT2, and T3 in each row
represents nomenclature for the images takem from the slide as mentioned in Figure 4-1 and
Figure 3-6.

Figure 4-13 shows the overall percent surface area coverage for this study,
averaged over the three thrombogenic regions and over three experiments for each L-A
concentration. The mean values gradually decrease with L-A concentration.
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Figure 4-13: Experimental results on overall percent surface area coverage with 0, 5, 10, and
15 µM L-A added at a shear rate of 1500 s-1. Error bars represent standard deviation.

Figure 4-14 shows adhesion divided into the different thrombogenic and nonthrombogenic regions. When L-A is added, the middle thrombogenic region tends to
have a smaller PSAC than the other two. T1 has a greater PSAC than T3 at 5 M, but a
smaller PSAC than T3 at 10 and 15 M. The non-thrombogenic regions show minimal
adhesion at all L-A concentrations.
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Figure 4-14: Experimental results on effect of percent surface area coverage for different
concentration of L-A on microchannel from upstream to downstream say T1-NT1-T2-NT2.
Error bars represent standard deviation.

4.4.1

Statistics
The PSAC decreased with increase in the concentration of L-A, with all values

being lesser than 1% at high concentration of L-A. The ANOVA single factor and two
factor test was performed to analyze the effect of different concentrations of L-A on
overall PSAC and on different thrombogenic regions of microchannel respectively.
The single factor analysis of variance shows the statistical significance difference
between the means of overall PSAC for three different concentration of L-A 5, 10, and
15M. The P values for the test was 0.0256 which is less than the α = 0.05 and F-statistic
value is higher than the critical value indicating that the null hypothesis for single factor
ANOVA is rejected. This p value suggested a significant difference in the adhesion
characteristics among L-A concentrations.
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The two factor ANOVA was performed to analyze the effect of PSAC on
microchannels by two factors, one of them was the thrombogenic regions from upstream
to downstream (T1, T2, and T3) and the other factor was the three different L-A
concentrations (5, 10, and 15M). The p values for three null hypothesis are 0.33, 0.003,
and 0.17 indicating that there is no statistical difference in means of PSAC for
thrombogenic regions T1, T2, and T3 and for different concentrations of L-A and tells
there exists no interaction between two factors for the α = 0.05 level. This led us to
believe that there is a no significant difference in the adhesion characteristics among
different thrombogenic regions with release of antagonists with different concentrations.
4.5

Effect of DPTA NONOate on PSAC

The high diffusion coefficient of NO and consequence of its small size has a
significant role in inhibiting activated platelets. To test the effect of NO in our system,
we added DPTA NONOate, an NO donor, at concentrations of 0 (control), 5, 10, and 15
µM to the CFSE-labeled PRP. The shear rate was 1500 s-1.
Figure 4-15 is a montage of sample images of the microchannels of both
thrombogenic and non-thrombogenic regions along the length of microchannel from
upstream to downstream perfused with different concentrations DPTA NONOate added
in CFSE-labeled PRP. DPTA NONOate concentration increases from the top row to the
bottom row. Platelet adhesion initially decreased as the concentration of DPTA
increased.
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Figure 4-15: Platelet adhesion under different concentrations of DPTA NONOate 0, 5,10 and,
15 µM/L in first, second, third row, and fourth row respectively. Images T1, NT1, T2, NT2, and
T3 in each row represents nomenclature for the images takem from the slide as mentioned in
Figure 4-1 and Figure 3-6.

Figure 4-16 shows the overall percent surface area coverage for each
concentration of DPTA. Each concentration of DPTA was repeated at least three times
with different blood samples, collected from the same animal on different days. Error
bars are the standard deviations for the three experiments. The PSAC for high
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concentrations of DPTA NONOate did not exceed the percent surface coverage for the
control. Thus, platelet adhesion was still inhibited at high DPTA concentrations.
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Figure 4-16: Experimental results on overall percent surface area coverage with 0, 5, 10, 15
µM/L DPTA NONOate added to the PRP, which was then perfused at a shear rate of 1500 s-1.
Error bars represent standard deviation.

Figure 4-17 shows PSAC for different concentration of DPTA NONOate on the
five microchannel regions from upstream to downstream. The PSAC pattern was not
consistent with the effect of DPTA NONOate concentrations on the microchannel along
the length of upstream to downstream. At lower concentrations i.e., 5 µM of DPTA
NONOate, PSAC decreased from T1 to T2 regions and increased from T2- T3. The
PSAC along the thrombogenic regions from upstream to downstream is an irregular
pattern and not consistent with the increase concentrations of DPTA NONOate.
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Figure 4-17: Experimental results on effect of percent surface area coverage for different
concentration of DPTA NONOate on microchannel from upstream to downstream say T1NT1-T2-NT2. Error bars represent standard deviation.

4.5.1

Statistics
The PSAC decreased with increase in the concentration of DPTA NONOate. The

ANOVA single factor and two factor test was performed to analyze the effect of different
concentrations of DPTA NONOate on overall PSAC and on different thrombogenic
regions of microchannel respectively.
The single factor analysis of variance shows the statistical significance difference
between the means of overall PSAC for three different concentration of DPTA NONOate
5, 10, and 15M. The P values for the test was 0.00037 which is less than the α = 0.05
and F-statistic value is higher than the critical value indicating that the null hypothesis for
single factor ANOVA is rejected. This p value suggested a significant difference in the
adhesion characteristics among DPTA NONOate concentrations.
The two factor ANOVA was performed to analyze the effect of PSAC on
microchannels by two factors, one of them was the thrombogenic regions from upstream
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to downstream (T1, T2, and T3) and the other factor was the three different DPTA
NONOate concentrations (5, 10, and 15M). The p values for three null hypothesis are
0.54, 0.10, and 0.49 indicating that there is no statistical difference in means of PSAC for
thrombogenic regions T1, T2, and T3 and for different concentrations of DPTA
NONOate and says that there exists no interaction between two factors for the α = 0.05
level. This led us to believe that there is a no significant difference in the adhesion
characteristics among different thrombogenic regions with release of antagonists with
different concentrations.
4.6

Combined Effect of ADP and LA on PSAC

Because ADP is a platelet activator and L-Arginine is a precursor for NO, a
platelet inhibitor, it is important to determine the combined effect of these two agents on
platelet adhesion to fibrinogen regions on the microchannel. ADP and LA were added
together to CFSE-labeled PRP according to the protocol described in the Chapter 3.6.
ADP concentrations were 0, 2, 5, and 10 µM, while L-Arginine concentrations were 0, 5,
10 and 15 µM.
Figure 4-18 shows overall adhesion on the microchannel for all combined
concentrations of ADP and LA. Each experiment, with each combination of combined
concentrations, was repeated at least three times with different blood samples (collected
from the same animal on different days). Error bars are the standard deviations for the
three experiments. When ADP concentration increased with LA concentration held
constant, platelet coverage increased, which indicates that platelets activated by ADP are
sufficient to counteract the effect of L-Arginine to increase the degree of adhesion of
platelets to fibrinogen. However, when L-Arginine concentration increased with ADP
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concentration held constant, PSAC decreased indicating that NO produced from platelets
by conversion of L-Arginine was sufficient to counteract the effect of ADP. Hence, these
observations support our hypothesis that platelet adhesion depends on the combined
effects of ADP and L-A or NO. In the experiments performed here, neither of the agent
completely nullified the effect of the other, supporting the hypothesis that platelet derived
NO serves as an inhibitor in negative feedback mechanism and ADP as activator in the
positive feedback mechanism of platelets.

% Surface Area Coverage

10

1

0.1
LA 5 LA 10 LA 15
ADP 0

LA 5 LA 10 LA 15
ADP2

LA5 LA10 LA15
ADP 5

LA5 LA10 LA15
ADP10

Figure 4-18: Overall platelet adhesion of platelets for all combination of different
concentrations of ADP and L-Arginine.

Figure 4-19 shows the PSAC results on the microchannel thrombogenic and nonthrombogenic. For the cases with 0 and 2 M ADP, PSAC is smaller for T2 than for T1,
suggesting that activation at T1 may inhibit adhesion at T2, possibly through the release
of NO. For larger ADP concentrations, the pattern was more irregular with respect to
fibrinogen region.
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Figure 4-19: Experimental results on effect of percent surface area coverage on combined
effect of ADP and LA for different combinations concentrations on microchannel from
upstream to downstream say T1-NT1-T2-NT2. Error bars represent standard deviation.

4.6.1

Statistics
The p value of the one factor ANOVA for the overall percent surface area

coverage, considering all combinations of ADP and L-A concentrations was 0.0084,
indicating that all treatment means are different and the difference among groups is
deemed statistically significance for modification of overall platelet adhesion by the
combined effect of ADP and L-A.
The p value of the two factor ANOVA for the interaction of combined effect of
ADP (2, 5,10 µM) and L-A (5, 10 and 15 µM) on different regions of microchannel from
upstream to downstream (T1, T2 and T3) is greater than 0.05, it means that F-statistic
value is small which tells that there is not much difference in all treatment means and the
difference among groups is not statistically significant. The p value for all the conditions
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comparing thrombogenic regions is 0.64, indicating no discernable differences in the
mean PSAC on the compared thrombogenic regions.
4.7

Combined Effect of ADP- DPTA NONOate on PSAC

DPTA NONOate spontaneously dissociates to generate NO with a half-life of
three hours at 37 °C and five hours at 22-25°C, pH 7.4 and can therefore replace deficient
levels of NO in patients with CAD. Replacement with exogenous NO donor benefits
patients with the impaired activity of the endothelial L-Arginine/NO pathway. DPTA
NONOate was added to the CFSE-labeled PRP prior to perfusion into the microchannels.
The half-life of DPTA NONOate obscured its combined effect with ADP. The results
were paradoxical and not constant throughout the experiments.
Figure 4-20 shows overall adhesion of the microchannel for all combined
concentrations of ADP and DPTA NONOate. Each experiment, with each combination
of combined concentrations, was repeated at least three times with different blood
samples collected from the same animal on different days. Error bars are the standard
deviations for three experiments.
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Figure 4-20: Overall platelet adhesion of platelets for all combination of different
concentrations of ADP and DPTA NONOate.

When ADP concentration increased with DPTA NONOate concentration held
constant, platelet coverage increased, which indicates that platelets activated by ADP are
sufficient to counteract the effect of DPTA NONOate and increase the degree of adhesion
of platelets to fibrinogen. However, when DPTA NONOate concentration increased with
ADP concentration held constant, PSAC decreased, except at ADP 10 µM concentration,
indicating that exogenous NO produced by DPTA NONOate donor and small amount of
endogenously developed NO was sufficient to counteract the effect of ADP at lower
concentrations but not at higher concentrations. However, ADP was totally neutralized at
higher concentration of DPTA NONOate, and platelet adhesion increased as ADP
concentration increased. These observations support our hypothesis that platelet
adhesion depends on the ratio of ADP to exogenous NO donor, but it suggests that
whether platelets are inhibited or activated depends on which agonist has the highest
concentration.
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Figure 4-21 shows the PSAC results for the five regions on the microchannel.
The PSAC values along the channel, from upstream to downstream of thrombogenic
regions did not show a consistent pattern with the combined ADP-DPTA NONOate
concentrations. Because DPTA NONOate and ADP have different sizes, different
diffusion coefficients and different half-life periods, it is reasonable to expect that their
transport characteristics will lead to different agonist/antagonist environment at different
thrombogenic regions surrounded by non-thrombogenic regions.
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Figure 4-21: Experimental results on effect of percent surface area coverage on combined
effect of ADP and DPTA NONOate for different combinations concentrations on microchannel
from upstream to downstream say T1-NT1-T2-NT2. Error bars represent standard deviation.

4.7.1

Statistics
The one-way ANOVA test results supports the alternative hypothesis that the

difference between the means of overall PSAC for all combinations of ADP (2, 5, and 10
µM) and DPTA NONOate (5, 10, and 15 µM) concentrations with p-value is less than
0.00001, indicating that all treatment means are different and the difference among
groups is deemed statistically significance for modification of overall platelet adhesion
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by the combined effect of ADP and DPTA NONOate. The two-way ANOVA tests were
used to analyze the PSAC for the combined effect of ADP and DPTA NONOate
considering all possible combinations of concentrations on thrombogenic regions T1, T2,
and T3 along the flow of the microchannel from upstream to downstream. The results
support all three null hypotheses because all three p-values are greater than 0.05
indicating no discernable differences in the mean PSAC with combined effect of ADP (2,
5, and 10 µM) and DPTA NONOate (5, 10, and 15 µM) considering all combinations on
the compared thrombogenic regions. Percent surface coverage values for these
conditions were small and therefore did not have a large enough range with the method
used to see a discernable difference between the two factors.
4.8
4.8.1

Calcium Activity in Platelets

Effect of ADP on Calcium Activity in Platelets
Upon stimulation of fluo-4/AM loaded platelets with ADP at different

concentrations, we observed a sharp calcium spike followed by another broad spike.
Each calcium spike consists of rise and decay phases which was due to change in
cytosolic calcium concentration. The spatial and temporal characteristics of calcium
spikes envisioned per cell depends on the ADP concentrations. The fluorescence
waveforms were monitored and analyzed to determine the changes in calcium peaks with
respect to ADP Concentrations (0, 2.5, 5, 10 µM). The calcium peaks obtained were
further analyzed to quantify the peak fluorescence intensity that corresponds to peak
calcium influx in the cell for all the treatment conditions in the experiment.
Figure 4-22 shows the images of calcium activity in platelets and changes in peak
fluorescence intensity before and after stimulating with ADP. Brighter blue colors
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indicate calcium influx into the platelet. The signal increases with the addition of ADP,
indicating platelet activation, with the secretion of Ca2+ into the cytoplasm. The signal is
increased to a greater extent with the addition of ionomycin, which increases Ca2+
permeability of the sarcoplasmic reticulum and releases Ca2+ into the cytoplasm. Thus,
ionomycin acts as a positive control to ensure that the calcium indicator functions
properly.

Figure 4-22: Calcium activity in platelets treated with activating stimulus (A) before
stimulation (control), (B) after ADP stimulation, and (C) after ionomycin stimulation (positive
control).

Fluo-4, single-wavelength indicators are not ideal with the quantitative
measurements because of the variations in fluorescence emission may not reflect
differences in Ca2+ concentration. To correct this uneven indicator concentrations, the
fluorescence signal is expressed in relative to its starting signal and is denoted as F/F0 or
∆F/F0 where F is the intensity of fluorescence emission recorded during experiment and
F0 is the fluorescence intensity at the start of the experiment.
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Figure 4-23: Calcium signals recorded for platelets when stimulated with agonists ADP 0,2,5,
and 10µM concentrations. The X-axis represents frame number and 1 frame = 4 seconds, Yaxis represents normalized fluorescent intensity values.

Figure 4-23 shows the calcium signals recorded for platelets when stimulated
with agonists ADP 0,2,5, and 10µM concentrations. Trial 5, Trail 16, Trial 26, Trial 31,
and Trial 59 are five ROIs selected among 150 to 200 ROIs on average per frame to
represent the data obtained for fluorescence intensity over time. The peak fluorescence,
showing a response above the normalized fluorescence (1 or 20% above the baseline),
after each stimulus increased with increase in ADP concentrations. The higher
concentrations of ADP (5 and 10 µM) caused an immediate rapid increase in [Ca2+],
followed by a slower decay phase that represents pumping of Ca2+ out of the cytosol.
Hence, most of the ADP stimulated platelets with higher concentrations have sharp rise in
calcium followed by a decay phase with repetitive transients in calcium.
Analyzing the peak Ca2+ fluorescence intensity can be used to support concentrationresponse relationships for different stimuli and helps in characterizing and measuring the
threshold and efficacy of stimulations on cellular responses. The averages of peak
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fluorescence intensity for each treatment conditions were calculated, and the values were
averaged over 3 experiments.
Figure 4-24 presents the analysis of peak calcium response that corresponds to
the normalized fluorescence intensity values above baseline (before stimulation), for
platelets stimulated with ADP concentrations 0, 2.5, 5, and 10 µM. Error bars represent
the standard deviations. Hence platelets stimulated with ADP showed significant
increase in the peak calcium response with increase in its concentrations.
The p value for the one-way ANOVA analyzing different ADP concentrations is
0.04, indicating significant difference in the adhesion characteristics between these
conditions.
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Figure 4-24: Graph showing the peak of the calcium response in platelets stimulated with
ADP. Each bar is the averages of N=3 experiments with two wells per condition, and with the
number of samples (cells) ranging from n=20 to 120. Error bars represent standard deviation
values.

4.8.2

Combined Effect of ADP and L-Arginine on Calcium Activity in Platelets
The inhibitor L-A (12.5 µM) was added to the ADP-stimulated (12.5 µM)

platelets in the wells, and Ca2+ spikes were recorded. The intensity of Ca2+ peaks
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decreased with addition of L-Arginine, with a small dilution artifact followed by a small
calcium peak indicating the inhibition effect of NO synthesized by L-Arginine on
calcium signaling.
Nitric oxide is powerful inhibitor for agonist-activated platelets and known to
decrease calcium concentration in cytoplasm which is elevated by agonists. NO
synthesized by L-Arginine by constitutive NO synthase in platelets speeds up the sarcoendoplasmic reticulum Ca2+ ATPase (SERCA)-dependent refilling of internal Ca2+ stores
by decreasing the calcium concentration in cytoplasm and has long been recognized to
inhibit platelet activation by increasing the synthesis of cyclic-3′5′-guanosine
monophosphate (cGMP) via direct stimulation of the enzyme soluble guanylate cyclase
(sGC). CGMP activates PKG, which blocks phospholipase C, which in turn blocks IP3
and decreases the intracellular calcium concentrations.
The fluorescence waveforms were monitored and analyzed to determine the
changes in calcium peaks in ADP stimulated platelets with respect to L-Arginine. The
data obtained for fluorescence intensity over time for each ROI were then normalized to
their starting values (baseline) in Microsoft Excel, for obtaining correlation between cells
within an experiment and with other experiments. The normalized values of fluorescence
intensity over time are represented using line graphs.
Figure 4-25 shows the normalized values of fluorescence over time for ADP
stimulated platelets and the effect of L-Arginine on them. The graph indicates
significantly inhibited Ca2+ response with the addition of L-A after stimulating platelets
with ADP to see the combined effect of ADP-LA on calcium activity. These findings
support the in vivo behavior of platelets depend on its calcium activity, where with low
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[Ca2+] indicates the secretion of inhibitor such as NO and high [Ca2+] levels indicate
secretion of activation agonists such as ADP. Trial 8, Trail 17, Trial 30, Trial 45, and
Trial 48 are five ROIs selected among 150 to 200 ROIs on average per frame to represent
the data obtained for fluorescence intensity over time.
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Figure 4-25: Calcium signals recorded for the ADP of 12.5 µM stimulated platelets with the
addition of L-A 12.5 µM. The X-axis represents frame number and 1 frame = 4 seconds, Yaxis represents normalized fluorescent intensity values.

Measuring and analyzing the peak Ca2+ fluorescence intensity helps in providing
concentration-response relationships for different stimuli. The calcium peaks obtained
were further analyzed to quantify the peak fluorescence intensity that corresponds to peak
calcium influx in the cell for all the treatment conditions in the experiment.
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Figure 4-26: Graph showing results for peak calcium response after L-A is added to
platelets stimulated with ADP to the normalized fluorescence intensities. Data represent the
averages of N=3 experiments with two wells per condition, and no. of samples (cells)
ranging from n= 20 to 120. Error bars represent standard deviation values.

Figure 4-26 shows the analysis of peak calcium response of ADP stimulated
platelets with addition of L-A. The data represents an average of 3 experiments and error
bar represents the standard deviations. Hence, addition of L-A to the ADP stimulated
platelets showed significant decrease in the peak calcium response by inhibiting the
intracellular [Ca2+]. The one-way ANOVA test for the fluorescent peak for different
stimulus on platelets yielded a p value of 0.01indicating a statistically significant effect at
the α=0.05 level.
4.8.3

Effect of ADP-DPTA NONOate on Calcium Activity
The platelets release the calcium from all the intracellular calcium stores upon

stimulus with ADP into cytoplasm. This process increases the cytoplasmic calcium
concentrations. The calcium released in the cytosol is either actively taken up by the ER
via calcium channels called Sarco-Endoplasmic reticulum Ca2+-ATPase (SERCA) or it is
flushed out through calcium channels present in plasma membrane. When DPTA
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NONOate, an exogenous NO donor, was added to ADP stimulated platelets, it
decomposes itself in PBS and activates Sarco-Endoplasmic reticulum Ca2+-ATPase
(SERCA) by decreasing the elevated calcium concentrations in ADP stimulated platelets.
The intensity of Ca2+ peaks were high with the addition of ADP and went low
with addition of NO donor, DPTA NONO when compared with the calcium peaks of
ADP stimulated platelets.
Figure 4-27 shows the normalized values of fluorescence over time for ADP
stimulated platelets and the effect of DPTA NONOate on them. Trial 56, Trail 74, Trial
81, Trial 96, and Trial 151 are five ROIs selected among 150 to 200 ROIs on average per
frame to represent the data obtained for fluorescence intensity over time. The elevations
of calcium spikes in ADP stimulated platelets before adding NO donors might vary in
between platelets or in between experiments due the physiological conditions of blood
and its behavior on different days.
The graph indicates significantly inhibited Ca2+ response with the addition of
DPTA NONOate after stimulating platelets with ADP to see the combined effect of
ADP-DPTA NONOate on calcium activity. These findings are consistent with the
inhibiting property of NO and shows that it leads to a reduction in intracellular [Ca2+].
The inhibition effect of DPTA NONOate on the elevated levels of calcium peaks in ADP
stimulated platelets is not much effective when compared with inhibition effect of L-A on
ADP stimulated platelets. The unstable nature of DPTNA NONOate, its short half-life,
and the ability of NO that can react with superoxide (O2 -) forming peroxy-nitrite
(ONOO-) were it exhibits both inhibitory and excitatory effects in platelets are few
factors which limits the inhibition rate of DPTA NONOate.
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Figure 4-27: Calcium signals recorded when DPTA NONOate is added to ADP-stimulated
platelets. The X-axis represents frame number and 1 frame = 4 seconds, Y-axis represents
normalized fluorescent intensity values.

Figure 4-28 shows the analysis of peak calcium response of ADP stimulated
platelets with addition of DPTA NONOate. The data represents an average of 3
experiments and error bar represents the standard deviations. The effect of DPTA
NONOate to the ADP stimulated platelets showed significant decrease in the peak
calcium response by inhibiting the intracellular [Ca2+]. The one-way ANOVA test for the
peak fluorescent intensities for different stimulus on platelets yielded a p value of 0.03
indicating a statistically significant effect at the α=0.05 level.
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Figure 4-28: Peak calcium response of DPTA NONOate on platelets stimulated with ADP to
the normalized fluorescence intensities. Data represent the averages of N=3 experiments with
two wells per condition, and no. of samples (cells) ranging from n= 20 to 120. Error bars
represent standard deviation values.

CHAPTER 5
DISCUSSION
A micro channel patterned with thrombogenic regions (coated with fibrinogen)
and non-thrombogenic region (coated with BSA) was created and used to study
simultaneous positive and negative feedback effects on regions in which thrombus
formation is active next to regions in which thrombus is prevented.
Many models which are being developed for platelet-mediated thrombo-genesis
considered the effects of platelet activators and inhibitors separately, but our
microchannel model helped us to study the combined effects of platelet derived activators
(ADP) and inhibitors (endogenous and exogenous NO donors) in one region influencing
platelets in a different region under varying shear conditions. The individual agents
ADP, L-Arginine, and DPTA-NONOate will be added to the PRP prior to injection
through the channels, and the amount of adhesion will be quantified as a function of the
concentration of each agent.
Agents like ADP and NO produced or released by activated platelets acts as
paracrine signaling molecules in activating other platelets in developing thrombus
formation. The signaling within a growing thrombus and signaling between two different
thrombi both are paracrine signaling but their effects differ depending on the agents
released and their concentrations, and agents released in one thrombogenic region
influencing the platelets on other thrombogenic region.
71

72
5.1

Effect of ADP Concentrations on PSAC

ADP is a well-known activator that enhances contact-induced activation of
platelets. However, it was important to demonstrate that agents such as ADP released by
platelets in a growing thrombus affect the growth of thrombus downstream. Multiple
thrombogenic surfaces arranged in the streamwise direction can help to verify this
hypothesis. The base slide consisted of thrombogenic regions (labeled T1, T2, and T3
from upstream to downstream) coated with fibrinogen from upstream to downstream.
These regions were separated by non-thrombogenic regions (NT1 and NT2) coated with
BSA. The base slides were perfused with CFSE-labeled platelets with different
concentrations of ADP (0, 2, 5, and 10 µM) at a shear rate 1500 s-1, and MATLAB was
used to calculate the PSAC from the fluorescent images.
Overall PSAC of the microchannel increased as ADP concentration increased,
and again the effect was dose dependent from Figure 4-10. High exogenous ADP
concentration (10 µM) on thrombogenic regions T1, T2, and T3 increased PSAC from
upstream to downstream because the endogenous and released ADP after platelets
activation overwhelmed the production of NO flowing from upstream to downstream.
Lower ADP concentrations (2 and 5 µM) increased PSAC at T1 and T2, but decreased
PSAC at T3, indicating that ADP at T1 would activate the platelets, causing them to
release more ADP which leads to increase PSAC at T2, but that NO produced at T1 and
T2 would flow downstream and inhibit PSAC at T3.
One-way and two-way ANOVA tests supported the alternative hypothesis overall
PSAC for the three concentration of ADP 2, 5, and 10 µM differ. They also supported
that the means of PSAC on different thrombogenic regions (T1, T2, and T3) differ.
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The P values for the one-way ANOVA test was 0.000315 and the p-values for
two-way ANOVA with three null hypothesis were 0.002, 0.000000426, and 0.03 which is
less than the α = 0.05 hence null hypotheses were rejected. This p value suggested a
significant difference in the adhesion characteristics among ADP concentrations with
different locations of thrombogenic regions.
5.2

Effect of L-Arginine on PSAC

NO inhibits the activation of platelets and prevents recruitment of additional
platelets to the platelet plug. The high diffusion coefficient of NO, a consequence of its
small size, has a significant role in inhibiting activated platelets. Experiments were
performed to determine whether the addition of L-Arginine, the precursor of NO, would
reduce the PSAC on the microchannel with thrombogenic and non-thrombogenic regions.
The images demonstrated reduced adhesion with increased L-Arginine qualitatively, and
the quantitative MATLAB analysis of these images demonstrated that the effect was dosedependent and repeatable.
The quantitative analysis states that overall PSAC of the microchannel decreases
with increased L-Arginine concentrations. The PSAC on the microchannel for different
concentrations of L-Arginine on different locations of thrombogenic regions T1, T2, and
T3 were small and therefore did not have a large enough range with the method used to
see a discernable difference between the two conditions. No significant results were
observed when comparing PSAC of T1, T2, and T3 with addition of L-A (5, 10, and 15
µM) concentrations. The one-way ANOVA and two-way ANOVA tests results
supported only the alternative hypothesis that the means of overall PSAC for three
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concentration of L-A 5, 10, and 15 µM are not same. The other hypotheses were rejected
(p > 0.05).
5.3

Effect of DPTA NONOate on PSAC

DPTA NONOate is the most available exogenous NO donor. The high diffusion
coefficient of NO enhances its transport to platelets, potentially enhancing its effect.
DPTA NONOate spontaneously releases NO with a half-life of three hours at 37 °C and
five hours at 22-25 °C, pH 7.4. Experiments were performed to determine whether the
addition exogenous NO donors modulated the bioactivity of endogenously produced NO
in platelets and whether the consequent increased NO levels reduce the PSAC on the
microchannel.
DPTA NONOate was added to the CFSE-labeled PRP prior to perfusion into the
microchannels. The overall PSAC initially decreased for lower concentrations of DPTA
NONOate (5 µM) and maintained a constant level at higher concentrations (15 and 20
µM). Though DPTA NONOate at higher concentrations did not continue to decrease the
overall PSAC significantly, PSAC did not exceed the levels of the control and maintained
a constant role in inhibiting the activated platelets.
The inhibition effect of DPTA NONOate on the microchannel was not same when
compared with inhibition effect of L-A, possibly because of difference in their
mechanism of action on platelets from upstream to downstream. DPTA NONOate,
which does not require the action of the platelets to produce NO whereas L-Arginine is a
precursor that stimulates production of NO by platelets. These different mechanisms of
NO production by L-Arginine and DPTA NONOate might affect the difference in PSAC
from upstream to downstream regions (T1-T2-T3). In the case of endogenous NO donor,
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L-Arginine, it stimulates NO in T1, and convection of that NO may inhibit thrombus on
T2, but not on T1, whereas DPTA NONOate, would possibly affect T1 and T2 by the
same amount due to exogenous production of NO is almost same on both the regions T1
and T2. This might be one of the reason where the mean PSAC values of T1 > T2 with
addition of L-Arginine for three different concentrations have different effect on
thrombogenic regions, though not statistically significant, in comparison to the DPTA
results where the mean PSAC values of T1≈T2 are intriguing.
The one-way ANOVA and two-way ANOVA tests results supported only the
alternative hypothesis that the difference between the means of overall PSAC for three
different concentration of DPTA NONOate 5, 10, and 15 µM are not same. All other
alternative hypotheses were rejected (p>0.05).
5.4

Combined Effect of ADP with Exogenous and Endogenous NO donors on
PSAC
The primary interest of this study is the combined effect of activator (ADP) and

inhibitor (NO) on platelet activation, adhesion, and recruitment. Both agents are present
in different amounts in any in vivo environment with absolute and relative concentrations
varying spatially because of local differences in their production and transport (both
diffusional and convective). The combination of both agents was added to CFSElabelled PRP prior to perfusion at different concentrations into microchannel.
5.4.1

Combined Effect of ADP-L-A on PSAC
With LA concentration held constant and ADP concentration increasing, the

overall PSAC increased, which indicates that ADP activation is still dose-dependent with
this baseline level of L-Arginine. Similarly, with ADP concentration held constant and

76
L-Arginine concentration increasing, the overall PSAC decreased indicating that NO
produced from platelets by conversion of L-Arginine is still dose-dependent with this
level of ADP. Hence, these observations support our hypothesis that platelet adhesion
depends on the combined effects of ADP and L-A or NO and that neither agent
completely erases the effect of the other. These results are consistent with a model in
which ADP is an activator in the positive feedback mechanism of platelet activation that
is modulated by a negative feedback loop that involves NO.
The one-way ANOVA test results supports the alternative hypothesis that the
means of overall PSAC for all combinations of ADP (2, 5, and 10 µM) and L-A (5, 10,
and 15 µM) vary, with p-value 0.0084.
Because L-A and ADP have different sizes and hence different diffusion
coefficients, it is reasonable to expect that their transport characteristics will lead to
different agonist/inhibitor environments at different regions within and near the
thrombus. However, different amounts of adhesion between upstream, middle, and
downstream thrombogenic regions did not show a clear pattern in studies on the
combined effect of ADP and L-A. The two-way ANOVA tests results rejected all three
null hypotheses (p>0.05). While further studies need to be carried out, to determine what
affect transport may have on the growth and the control of thrombus growth.
5.4.2

Combined Effect of ADP- DPTA NONOate on PSAC
When DPTA NONOate concentration was held constant while ADP

concentration was increased, platelet coverage increased. Thus, ADP acts in a dosedependent manner at the constant level of DPTA NONOate. Similarly, when ADP
concentration was held constant while DPTA NONOate concentration increased, PSAC
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decreased, except at ADP 10 µM concentration, indicating that, in general, neither agent
negated the effect of the other but that the high ADP level was sufficient to negate the
effect of DPTA at the concentrations used. These observations support our hypothesis
that platelet adhesion depends on the relative concentrations of ADP and NO donor.
The one-way ANOVA test result supports the alternative hypothesis that overall
PSAC varies for all combinations of ADP (2, 5, and 10 µM) and DPTA NONOate (5, 10,
and 15 µM) concentrations (p<0.00001). Two-way ANOVA tests were used to analyze
the PSAC for the combined effect of ADP and DPTA NONOate, considering all possible
combinations of concentrations on thrombogenic regions T1, T2, and T3 along the flow
direction of the microchannel. The results support the null hypothesis for all three
regions (p>0.05). Percent surface coverage values for these conditions were small and
may not have had sufficient range, with the method used, to discern differences between
the two factors.
5.5

Effect of ADP, L-A, and DPTA NONOate on Calcium Signaling

Platelet derived activators (ADP) and inhibitors (NO) not only effect the
thrombus formation but also increases the cytosolic calcium concentration of platelets
when activated. Activation and inhibition pathways of platelets trigger calcium stores in
platelets at site of thrombus formation. Increase or decrease in cytosolic Ca2+
concentration plays a crucial role in platelet activation and could lead to accelerated
thrombus growth or decelerated thrombus growth, depending on whether the activators or
the inhibitors from the upstream thrombus are more dominant.
Platelet agonists release Ca2+ from intracellular stores during platelet activation
plays a crucial role in regulating many platelet functions. Increase in calcium
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concentration in platelets are due to the release of Ca2+ from compartments and entry of
extracellular Ca2+ through plasma membrane. Calcium signaling in activated platelets
through agonists acts as paracrine signals. These signals usually produce quick responses
which lasts for only short time. The interplay between positive and negative feedback
with respect to calcium signaling is largely unknown. We evaluated calcium release in
vitro at single cell level in free moving cells, while neglecting the effect of NO release in
inhibiting calcium concentrations. Platelet poor plasma was loaded with Fluo-4 Ca2+ ion
indicators, and the fluorescence waveform was measured and analyzed after addition of
ADP and NO donors (exogenous and endogenous). Most of the experiments
demonstrated an agonist-induced platelet activation that involved a sharp increase in
intracellular calcium ions [68][69].
Calcium response increased with increased ADP concentrations (0, 2.5, 5, 12.5
µM) and had a greater number of significant calcium oscillations when compared to
calcium response produced with addition of L-A/DPTA NONOate. A significant
decrease in calcium response was observed with these latter two agents.
5.6

Effects of Shear Rates

Shear rate is one of the main factor that affect the processes that control the rate of
thrombus formation [70]. The higher shear rates from 1000 – 10,000 s-1 were found in
atherosclerotic lesions, preexisting thrombi, regions of moderate arterial stenosis and
platelet-platelet interactions which results in prothrombotic microenvironment [71][72].
The base slide of the microchannel was coated with fibrinogen to produce a
thrombogenic surface and evaluated platelet adhesion at a shear rate of 1500 s-1
representing the shear rate different conditions of adding no chemicals and varying
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amounts of ADP, L-A and DPTA NONOate. Due to the time limitations, we were unable
to run few more set of experiments at different shear rate and unable to evaluate the effect
of shear rate on these hypotheses.
There were no direct comparisons found for the method used in this work all
through the literature at shear rate 1500 s-1 to compare the results of combined effects of
LA-ADP/DPTA NONOate on platelet adhesion. Sanakam and Adams results showed
that L-A added to PRP saw an overall increase in adhesion at 1500 s-1 compared a lower
shear rate of 500 s-1 for the microchannel with thrombogenic region size of 6mm X 6mm
and 8mm X 8mm coated with fibrinogen, which did not agree with the results of
Watson’s method where he used a fibrinogen coating to investigate the effect of shear
rates and saw a reduction in overall adhesion at higher shear rates with addition of L-A
[33][34][62]. Our results by using the similar method as Sanakam and Adams did, but
with thrombogenic regions of size 2mmX2mm coated with fibrinogen for different
concentrations of L-A and DPTA NONOate, showed reduction in platelet adhesion in
agreement with the results of Watson’s method [62]. The results for the combined effect
of ADP- L-A/ ADP- DPTA NONOate on platelet adhesion at different thrombogenic
regions for different concentrations of L-A/ADP/DPTA NONOate were inconclusive and
shear rate might be one of the reason altering the effect of T1 on T2 and T2 on T3.
5.7

Comparison of Results to Other Sources

Sihui Xu and his team developed a microfluidic device to study platelet adhesion
and aggregation under shear flow pathophysiological conditions. Platelet activation in
upstream was performed either by using agonists or by shear flow and platelet adhesion
in downstream was caused by collagen-coated microbeads loaded in tube [73]. Their
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results showed that platelet adhesion in downstream was dependent on platelet activation
in upstream including parameters like shear rate (754-2400 s-1), shearing time (>10 s),
and incubation time (>20 s). They also produced real-time of platelet related thrombus
formation by combining a variety of leading-edge technical elements. The portion of
their results agreed with the results of our work were the effect of platelet adhesion on the
downstream region with the addition of chemical agents depends on platelet activation in
upstream regions and agents released by platelets.
Shekh Rahman and Vladimir Hlady developed a microfluidic system consists of
flow channel with upstream stenotic region and downstream protein capture region to
perfuse whole blood and used to evaluate the effect of antiplatelet agents inhibiting
platelet adhesion under shear flow. Platelet binding proteins like collagen, fibrinogen and
vWf were patterned using microcontact printing on the surface of downstream capture
region. Whole blood with antiplatelet agent was perfused through upstream region under
shear rate ranging from 4860 to 11560 s−1. Their results showed that Acetylsalicylic acid
failed in inhibiting shear-induced platelet adhesion to all three binding proteins whereas
GPIIb/IIIa inhibitors (tirofiban and eptifibatide) significantly inhibited platelet adhesion
to fibrinogen. Platelet adhesion reduced with all three capture proteins by blocking
antibody of vWf or GPIbα [74]. The portion of their hypothesis evaluating the effect of
platelet adhesion for different group of antiplatelet agents like GPIIb/IIIa inhibitors under
shear flow conditions was almost similar to our hypothesis where platelet adhesion
decreases with the addition of NO inhibitors under the influence of shear rate 1500 s-1 on
a microchannel with thrombogenic regions coated with fibrinogen.
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Avtaeva and his team introduced a testing system for real time recording of the
platelet kinetics adhered to fibrinogen-coated surface under flow conditions. Their
system consists of an optical flow chamber, semiconductor laser, two photodetectors,
analog to digital converter, computer, and peristaltic pump. Photodetectors were used to
record the platelet adhesion to fibrinogen coated optical surface and analyzed the
intensity of total internal reflection and scattered laser radiation [75]. A function of shear
rate and platelet concentration was used to study the platelet adhesion kinetics and its
specificity was verified by blocking IIb/IIIa glycoprotein complex on platelets by using
Fab2 fragments of monoclonal antibodies. These results by their testing system show
that kinetics of adhesion of ADP-activated platelets to protein-coated surface under
controlled f low conditions were recorded effectively and were in accordance with the
results of effect of ADP on platelet adhesion on microchannel coated with fibrinogen.
J.E. Freedman’s study said that NO when released by platelets inhibits further
recruitment of platelets forming a thrombus. The thrombotic response can be altered by
modulating endogenous platelets and regulate several clinical diseases with low NO
bioactivity and bioavailability, by replacing with exogenous NO donors [16][76][77][78].
This result agrees with the results of this work. L-A that produced by oxidizing
constitutive nitric oxide synthase (cNOS) was used in this work and observed the results
that reduced platelet activation and recruitment. The results of these experiments agreed
with the results of our work where with the addition of L-A decreases the overall PSAC
of platelets adhered to the microchannel.
A procedure demonstrated by Bellavite and his colleague through a colorimetric
method for the measurement of platelet adhesion in microtiter plates by ADP and
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thrombin stimulated platelet adhesion in dose dependent manner to fibrinogen but not to
albumin [68]. The results determined in these experiments agreed with the results of our
work where the overall PSAC of the microchannel increased in dose dependent manner
with effect of ADP.
A study done at University of Oklahoma and Baptist Medical Center located in
Oklahoma explained the link between the region space and platelet aggregation where the
method used for this investigation was different from the method used our work with
isolated thrombogenic regions as opposed to lines across the slide or down the slide used
for thrombogenic regions. This work was done at a lower shear rate of 100 s -1 in
contrast to our work at higher shear rates of 500 s -1 and 1500 s -1 and results were
inconclusive when compared [69].
5.8

Sources of Experimental Errors

The experiments were lengthy, and because platelet function can change rapidly
after blood is removed from the host, most of the process had to be done in one day. This
requirement limited the number of trials that could be done for a given condition. The
main sources of error in these experiments were time delay.
Some manual errors may occur while pasting Kapton tape on the slide in the right
position, while sandwiching the tape and glass slide consistently each time manufacturing
the microchannel. The accuracy in Kapton tape cutting in desired shape and size and
accuracy in drilling the inlet and outlet holes depends on the cutters machine and driller
machines precision respectively.
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5.9

Variability in Experiments

Patterning of thrombogenic regions with fibrinogen manually should be consistent
and accurate along the channel to see the change in PSAC on different thrombogenic
regions. A method which provides higher accuracy values for patterning proteins should
be developed. The thickness of the fibrinogen and BSA layers should also be quantified
using X-ray reflectivity (XRR) and atomic force microscopy (AFM) methods [79].
Consistent variability along the channel, or from region to region, could affect the
amount of adhesion, and thus the interpretation of the results.
Systematic investigation was needed to determine the optimal flow rates for
rinsing and drying to avoid droplets and debris at imaging stage. Insufficient rinsing and
drying leads to artifacts in the imaging.
The samples of bovine blood collected from Tech Farms needed to be properly
mixed with anticoagulant to avoid the blood clots and then used in the same day. The
platelets extraction from blood is recommended within first two hours. The physiological
conditions of blood can differ with samples each day, even though the samples were from
same source and hence expected some variability in platelets count [80] [81].
DPTA NONOate is the most available exogenous NO donor with high diffusion
coefficient of NO and consequence of its small size has a significant role in inhibiting
activated platelets. DPTA NONOate spontaneously dissociates NO with a half-life of
three hours at 37°C and five hours at 22-25°C, pH 7.4. DPTA NONOate, when not used
before its half-life period expires, will exhibit a substantial reduction in its inhibition
effect. For a given NO donor, DPTA NONOate with a half-life of 5 hours, the initial NO
concentration will be approximately 0.54 x 10-3 times the initial donor concentration
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(millimolar concentrations of donor yield nanomolar concentrations of NO. The expected
concentration of NO, for the given the concentrations of 5, 10, and 15µM DPTA
NONOate were 2.7, 5.4, and 8.1nM respectively which were greater than the minimum
NO concentration required to inhibit platelets under all conditions that is 0.15nM [66].

CHAPTER 6
CONCLUSIONS AND FUTURE WORK

6.1

Conclusions

The results from the microchannel experiments suggest the following
conclusions.
•

Percent surface area coverage of platelets will increase dose-dependently when
platelet derived activators (e.g., ADP) are included and decrease dosedependently when NO donors (L-A and DPTA NONOate) are included in the
perfused plasma.

•

Adhesion increased when L-Arginine concentration was held constant and ADP
concentration was increased. Furthermore, when ADP concentration was
increased and L-Arginine concentration was held constant, platelet adhesion
decreased. Neither ADP nor NO was completely neutralized by the other agent at
any of the concentrations used in this study.

•

For a fixed amount of DPTA-NONOate added to the PRP, platelet surface area
coverage increased with increased plasma ADP concentration. Likewise, for a
fixed amount of ADP added to the plasma, platelet surface area coverage
decreased with increased DPTA-NONOate concentration.

•

Calcium response in plasma free platelets loaded with the fluorescent Ca2+
indicator Fluo-4 increased dose-dependently with addition of an activator, ADP.
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•

Calcium response in ADP stimulated platelets decreases with addition of L-A
indicating the immediate inhibition effect of NO synthase endogenously in ADP
stimulated platelets.

•

Addition of exogenous NO donor DPTA-NONOate, with the intent to overwhelm
the endogenous feedback through platelet NO production, decreased [Ca2+] peaks.
6.2

6.2.1

Future Work

Platelets Count
Platelet count was not quantified in these studies. Although the blood samples are

from the same source, we expected variability in platelet count from sample to sample.
Counting platelets before experiments might improve statistical analysis and decrease the
variability in results. Testing platelet samples independently in an aggregometer before
each experiment to determine the changes in platelet activity in each sample and correlate
it to the behavior of the microchannel under flow would give better results.
6.2.2

Patterning of Proteins Using Nano eNabler
Patterning proteins like fibrinogen or collagen on thrombogenic regions of size 2

mm by 2 mm manually is very hard to be precise, accurate and repeatable. The Nano
Enabler is the tool used to lay proteins in minute volumes of liquid at specified positions
as designed with high spatial accuracy by reducing clogging. Experiments preparing the
base slide of the microchannel this way would give the ability to do more complicated
experiments. All conditions evaluated in this dissertation would need to be repeated
using this modification to the method.
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6.2.3

Effect of Proteins on Platelet Adhesion
Proteins like fibrinogen and collagen play a key role in thrombus formation and

are considered as important ligands for platelet adhesion to artificial surfaces. The time
limit and the need for blood samples to be used on same day, prevented experiments for
microchannel patterned with collagen on thrombogenic regions and examine their effect
on platelet adhesion. All conditions evaluated in this dissertation would need to be
repeated using this modification to the method.
6.2.4

Real-Time Analysis
Real-time analysis would benefit the platelet adhesion study because we could

closely monitor the platelets adhering to thrombogenic and non-thrombogenic regions
and effect of activators and inhibitors on it. The system can be modified to allow
visualization of the surface during the flow experiment with a video camera.
6.2.5

Combined Effect of ADP- DPTA NONOate on PSAC
All the calcium signaling experiments in this dissertation were done using 96 well

flat plates with high affinity were recorded. The experiments were then analyzed in
InCyt Im™ Imaging System software in real-time. Additional information could be
obtained if a method were devised to examine calcium signaling in platelets with addition
of exogenous and endogenous agents on microchannel with thrombogenic patterned with
fibrinogen or collagen and non-thrombogenic regions blocked BSA under different shear
rates with InCyt Im™ Imaging System software in real-time.
6.3

Future Applications

The model used here is not only translatable to cardiovascular diseases like
atherosclerosis with mor irregular and frequently diffuse pattern of platelet adhesion and
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thrombosis, but the findings may also extend to stent development. The methods used in
dissertation can be further used to assess the efficacy of anti-platelet treatments of a stent
that has multiple thrombogenic and non-thrombogenic regions with platelet recruitment.
These methods are useful while designing stents which were coated with anti-platelet
drugs for example a stent that is coated with a Nitric Oxide (NO) donor could have
multiple separated regions of NO release and thrombogenic tissue, will greatly diminish
the thrombus that forms on stents and consequently reduce complications of occlusive
thrombosis and intimal hyperplasia.

APPENDIX A
PROGRAM USED TO CALCULATE PSAC

% Collect the names of all subdirectories in "folders."
thresh = 30;
files = dir('E*');
dirflags = [files.isdir];
directories = files(dirflags);
% Create an Excel file that contains the percent coverage values for
all
% files.
w = what;
mypath = w.path;
xlsfilename = [mypath '\' 'Percentages.xls'];
ExcelFileLine = 1;
% Print folder names to command window.
for k = 1 : length(directories)
folder = directories(k).name;
Subfoldername = {folder};
fprintf('Sub folder #%d = %s\n', k, folder);
thecell = sprintf('A%d',ExcelFileLine);
ExcelFileLine = ExcelFileLine + 1;
[stat msg] =
xlswrite(xlsfilename,Subfoldername,'Percentages',thecell)
[pct ExcelFileLine] = doimg(folder,thresh, ExcelFileLine,
xlsfilename);
ExcelFileLine = ExcelFileLine + 1;
end

function [pct LineNo] = doimg(foldername,thresh,ExcelFileLine,
xlsfilename)
% Process and image
% Get the name of the folder in which the images are kept.
% ****** Change this name for different directories
% foldername = 'E1S1R1C2L-NMMA';
% Change the threshold, if necessary.
and
% 255.
thresh = 30.

It should have a value between 0

% Get the screen heigh and width (to place the plots on the screen).
scrsz = get(0,'ScreenSize');
wid = scrsz(3);
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hgt = scrsz(4);
% Find the current working directory (so that you can find the image
file
% namse).
w = what;
mypath = w.path;
imgs = [foldername '/' '*.tif']; % Full path of the folder where the
images are kept.
% Create a list of all image files in the image folder.
allimgs = dir(imgs);
% Find out how many image files are in that folder.
s = size(allimgs);
Ntotal = s(1);
% For each file in the folder, process the image.
f1 = figure(1);
f2 = figure(2);
for i = 1:Ntotal
fullfilename = [foldername '\' allimgs(i).name]; % Full path name
of the file.
% Read the image into MATLAB as an array I.
I=imread(fullfilename);
% Uncomment the next three lines if you want MATLAB to show the original
image.
%
Title = ['Original ' allimgs(i).name]
%
figure('Name',['Original ' allimgs(i).name],'Position',[wid/10
hgt/1.8 wid/3 hgt/3]);
%
image(I);
% Resize the image to a more managable heigh and width.
Ismall = imgresize(I,384,512);
close(f1);
close(f2);
f1 = figure('Name',['Small ' allimgs(i).name],'Position',[5*wid/10
hgt/1.8 wid/3 hgt/3]);
image(Ismall);
% The Mex file threshold.mex changes the image to grayscale and then
sets
% all pixels greaterh than thresh to 255 and all pixels less than
thresh to
% 0.
[Ithresh pct] = threshold(Ismall,thresh);
% Subtract 0.1770 from the percent coverage. This is the percent of
the
% image that is covered by the length scale label. It would be better
to
% account for the label in some other way, but we will go with this for
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% now.
pct = pct - .1770;
% Show the thresholded figure
f2 = figure('Name',['Threshold '
allimgs(i).name],'Position',[5*wid/10 hgt/10 wid/3 hgt/3]);
imshow(Ithresh);
% Write the percentage data to the Excel file.
thename = {allimgs(i).name, pct};
thecell = sprintf('A%d',ExcelFileLine);
[stat msg] = xlswrite(xlsfilename,thename,'Percentages',thecell)
ExcelFileLine = ExcelFileLine + 1;
LineNo = ExcelFileLine;
% Uncomment the next line to clear all figures
%close all
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